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Worldwide, gastric cancer is one of the most common cancers and the second 
leading cause of cancer death. Alternative splicing is known to sometimes play a role in 
cancer in general, and specifically in gastric cancer. However, little is known about the 
full breadth of the effects of alternative splicing in gastric tumorigenesis. To 
systematically investigate this, this study used massively parallel next generation 
sequencing to sequence the mRNA populations of (1) 12 gastric adenocarcinomas and 
matched non-malignant gastric mucosa and (2) 10 gastric adenocarcinoma cell lines. The 
study identified 320 genes with likely private cancer-associated spliceforms, and found 
that these genes were significantly enriched for functions related to cell-cell interaction 
and cytoskeletal function, themes that have been observed in splicing changes in the 
epithelial-mesenchymal transition in breast cancers. To assess the generality of the 
association of spliceforms with gastric cancer, I also used RT-PCR in an independent 
group of tumors and matched normal tissues. This study identified gastric-cancer-
associated alternative spliceforms that were not previously linked to this disease, and 
some of these spliceforms, those in COL6A3 and FLNA, were predominately tumor-
specific in our samples. Thus, it is likely that alternative splicing indeed plays a 
substantial role in gastric carcinogenesis, and the list of gastric-cancer-associated 
spliceforms identified in this study should provide a foundation for further experimental 
investigation of the effects of particular spliceforms.  
Following that, this study then presents a comparison of two technologies for 
assessing alternative splicing: RNA-seq and exon arrays. Surprisingly, the study finds 
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that because of the details of their designs, the two technologies detect largely disjoint 
sets of alternative splicing events.  
Finally, I present work that I did to detect and validate the effects of an extremely 
mutagenic herbal remedy on splicing in upper urinary tract cancers. The mutations 
caused by this herbal remedy usually mutate CAG trinucleotides to CTG. The CAG 
trinucleotide is found at the majority of human 3’ splice sites, and I showed that 
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1. Chapter 1 Introduction and literature review 
1.1. Gastric cancer 
Gastric cancer is defined as a cancer that forms in tissues of the stomach (NCI 
http://www.cancer.gov/stomach). Gastric cancer is a severe type of cancer with high 
incidence, high mortality, high prevalence and low 5-year survival rates. The following 
subsections provide details of the epidemiology, clinical characteristics, and steps of 
cancer progression. 
1.1.1. Epidemiology 
Although the incidence of gastric cancer has declined in recent decades, gastric cancer is 
still a leading cause of cancer-related death worldwide, with mortality second only to 
lung cancer (Ferlay et al., 2010; Garcia M, 2007). It also has the fourth highest incidence 
(Ferlay et al., 2010; Garcia M, 2007). In 2007, stomach cancer resulted in approximately 
0.8 million deaths worldwide (Figure 1), accounting for the deaths of 511,419 males and 
288,681 females (Garcia M, 2007). In particular, gastric cancer is highly prevalent in East 
Asia (Figure 2) (Crew and Neugut, 2006).   
 
Figure 1 Worldwide deaths in 2007 from the cancers with highest lethality. 














Figure 2 Incidence of stomach cancer. 
(Reproduced with permission from (Crew and Neugut, 2006).) 
1.1.2. Clinical characteristics 
1.1.2.1. Classification 
Gastric tumors can be classified into four subtypes: gastric adenocarcinoma, lymphomas, 
stromal tumors, and rare tumors (Layke and Lopez, 2004). Gastric adenocarcinomas 
account for 95% of malignant gastric tumors and are histologically heterogenous both 
architecturally and cytologically. Gastric adenocarcinomas are often histologically 
subdivided into two main types according to Lauren's criteria: intestinal and diffuse(Crew 
and Neugut, 2006). Intestinal subtype adenocarcinomas are more common in older 
people and are associated with intestinal metaplasia and Helicobacter pylori infection, 
while diffuse subtype adenocarcinomas tend to be observed in young and female 
populations (Hu et al., 2012). 
In 2010, the World Health Organization (WHO) proposed another classification of gastric 
cancers as shown in Table 1. 
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Table 1 WHO 2010 classification vs. Lauren classification 
WHO (2010) Lauren (1965) 
Papillary adenocarcinoma Intestinal type 
Tubular adenocarcinoma 
Mucinous adenocarcinoma 
Signet-ring cell carcinoma Diffuse type 
Other poorly cohesive carcinoma 
Mixed carcinoma Indeterminate type 
Papillary adenocarcinoma tends to affect older people, and poorly cohesive carcinomas 
(e.g. signet ring cell carcinoma) tend to exhibit lymphatic vascular invasion and lymph 
node metastasis (Hu et al., 2012). 
1.1.2.2. Tumor staging 
Tumors arising in the stomach can be staged according to depth of tumor invasion, 
presence or absence of lymph node metastasis, and presence or absence of distant 
metastasis (Hye Seung Han, 2010) as shown in Table 2.  
A combination of primary tumor (T), regional lymph nodes (N), and distant metastasis 
(M) categories provides a single staging description as shown in Table 2. As the tumor 
stage increases, the 5-year survival rates for curative surgical resection dramatically 




Table 2 Clinical staging of gastric cancer from (Layke and Lopez, 2004) 
Stages Description 
Stage 0 Limited to the inner lining of the stomach 
Stage I Penetration to the second or third layers of the stomach (Stage 1A) or to the 
second layer and nearby lymph nodes (Stage 1B) 
Stage II Penetration to the second layer and more distant lymph nodes; Or the third 




Penetration to the third layer and more distant lymph nodes, or penetration to 




Cancer has spread to nearby tissues and more distant lymph nodes, or has 
metastasized to other organs. 
1.1.2.3. Pathogenic factors 
Gastric cancer is a multifactorial disease (Crew and Neugut, 2006). Risk factors include 
diet, smoking, H. pylori infection, previous gastric surgery, obesity, radiation exposure 
and genetic factors (Crew and Neugut, 2006). Among these risk factors, the most studied 
factor is H. pylori infection. According to one model, this triggers progressive changes in 
the gastric epithelium, starting chronic gastritis and culminating in gastric 
adenocarcinoma (Correa, 1996; Forman et al., 1991; Nomura et al., 1991; Parsonnet et al., 
1991; The EUROGAST Study Group, 1993) 
The complicated molecular perturbations reveal the heterogeneity of gastric cancer. 
1.1.3. Steps of cancer progression 
Pathological and epidemiological evidence indicate that gastric carcinogenesis is a 
multistep and multifactorial process. In one theory, the normal gastric epithelium 
progresses to carcinoma in the following sequential stages: superficial gastritis, atrophic 
gastritis, small intestine metaplasia, colonic metaplasia, and dysplasia (Correa, 1992). In 
this model, H.pylori plays a causal role in transforming normal epithelium to superficial 
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gastritis (Nomura et al., 1991). Excessive salt intake induces mucosal damage and 
atrophy (Correa et al., 1975; Kodama et al., 1984) and causes excessive cell replication 
(Correa, 1992). Lack of ascorbic acid promotes the transition from atrophic gastritis to 
metaplastic mucosa by increasing gastric pH and the proliferation of anaerobic bacteria 
that produce nitroso mutagens and carcinogens (Correa, 1992). 
1.2. Alterations in gastric cancer 
1.2.1. Genetic and epigenetic alterations in gastric cancer 
At a molecular level, gastric cancer is heterogeneous and its development is not caused 
by a single factor, but rather by an accumulation of multiple genetic and epigenetic 
alterations (Panani, 2008). Studies of genetic alterations in gastric cancer have shown a 
bewildering variety of perturbations (Blok et al., 1997; Panani, 2008; Werner et al., 2001) 
including single nucleotide mutations, copy number alterations, and loss of 
heterozygosity (LOH). 
The most commonly mutated genes in gastric cancer that contribute to tumorigenesis 
and/or tumor progression are TP53, PTEN, CTNNB1 (Hudler, 2012; Nobili et al., 2011; 
Oki et al., 2012; Panani, 2008; Park et al., 1999; Yamashita et al., 2011), and ARID1A 
(Wang et al., 2011; Zang et al., 2012), while less common driver genes include FAT4 
(Zang et al., 2012). Other commonly mutated genes including PIK3CA (Li et al., 2005), 
APC (Nakatsuru et al., 1992), CDH1(Becker et al., 1994; Guilford et al., 1998) may be 
associated with gastric cancer . Genes amplified in gastric cancer include KRAS, ERBB2, 
HER2, FGFR2, PI3KCA and MET and patients with these genes amplified are associated 
with poor survival (Deng et al., 2012; Nobili et al., 2011; Yamashita et al., 2011). Genes 
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frequently altered by LOH in gastric cancer include APC, BCL2, CDH1, TP53 and PTEN 
(Hudler, 2012; Oki et al., 2012; Yamashita et al., 2011) and LOH of CDH1 increases 
invasive capacity (Yamashita et al., 2011). 
Studies of epigenetic alterations in gastric cancer include disregulation of expression, 
hypermethylation or hypomethylation, acetylation and miRNA expression change. Genes 
with altered methylation in gastric cancer include two tumor suppressor genes: DKK3, 
MGMT and other genes: APC, CACNA2D3, CDH1, CDKN2A, PCDH10, PTEN, SOX2, 
and TFPI2 that associated with shorter survival rate (Nobili et al., 2011; Zouridis et al., 
2012).Sup Table 1 summarizes genetic and epigenetic changes in genes implicated in 
gastric cancer. 
1.3. Aberrant alternative splicing 
Apart from the genetic and epigenetic alterations above, alternative splicing (AS) has 
been reported to play an important role in gastric cancer (Okoniewski and Miller, 2008). 
1.3.1. Definition of alternative splicing 
Alternative splicing is a process that produces multiple transcripts from a single genetic 
locus, thereby increasing the genomic coding potential (Moore and Silver, 2008). 
Transcripts produced from the same pre-mRNA consist of exons that encode different 
amino-acids, and contain distinct protein domains and modification sites. Thus, the 
proteins encoded by these transcripts may differ in sub-cellular localization, structure, 
phosphorylation sites, and  susceptibility to proteasomal degradation (Venables, 2006).   
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The process of alternative splicing can produce distinct mRNAs by seven different 
mechanisms: exon skipping, intron retention, mutually exclusive exons, alternative 5' 
splice site, alternative 3' splice site, alternative transcripts initiation, and alternative 
polyadenylation (Figure 4). In Figure 4, green boxes represent flanking exons while light 
blue and dark blue boxes represent exons affected by alternative splicing. Use of 
alternative exons produces different transcripts, and the encoded proteins function 




Figure 3 Different modes of alternative splicing. 
Green boxes represent flanking exons while light blue and dark blue boxes represent 




1.3.2. Operation of the splicing machinery 
During the splicing process, introns must be excised precisely and exons must be 
selectively joined in order to form mRNAs that encode distinct proteins (Maniatis and 
Tasic, 2002; Srebrow and Kornblihtt, 2006). At the exon-intron boundaries, the splice site 
sequences are positioned and recognized by snRNAs via base pairing (Wang and Cooper, 
2007). In combination with the splice site sequences, additional extensive and complex 
cis- and trans-elements are essential for regulation of splicing (Miura et al., 2011; Wang 
and Cooper, 2007). Cis-elements include intronic splicing enhancers (ISEs), exonic 
splicing enhancers (ESEs), exonic splicing suppressors (ESSs) and intronic splicing 
suppressors (ISSs). The trans-elements include components of the spliceosome. 
 
Figure 4 Components of the splicing mechanism. 




In the initial steps of splicing (Figure 4), the spliceosome recognizes the 5' donor splice 
site sequence (GU) and the 3' acceptor splice site (AG). The minor spliceosome 
recognizes AU and AC instead. The spliceosome recruits U1 snRNP to the GU 
dinucleotide at the 5' splice site and the smaller subunit of the U2 auxiliary factor 
U2AF35 to the AG dinucleotide of the 3' splice site (Yoshida et al., 2011). Following that, 
another U2 auxiliary factor (a U2AF65-U2AF2 heterodimer) helps to recruit the U2 
snRNP containing splicing factors A1 and B1 (SF3A1 and SF3B1, lower right of Figure 
4). Then, splicing factor 1 (SF1) binds to branch point motif (UACUAAC) with the 
interaction of U2 auxiliary factor (U2AF). At the same time, a group of serine/arginine-
rich proteins (SR proteins, SRp, e.g. SRSF1, SRSF2) as well as SR-like proteins (e.g. 
splicing factor 2, SF2) bind to the exonic splicing enhancer (ESE in Figure 4) with the 
interaction of U2AF35 (Miura et al., 2011). This recruitment helps stabilize the binding 
of spliceosome components (e.g. U2AF) binding to ESEs (Wang and Cooper, 2007). 
Finally, ZRSR2 interacts with U2AF65, SRSF1, and SRSF2 to form a close structure to 
FU2AF35 which then generates the splicing complex (Wang and Cooper, 2007; Yoshida 
et al., 2011) and splice out intron sequence.  
Perturbations at any step of this process can alter splicing. In cancers in general, splicing 
can be altered by mutations at splice sites or other cis-elements (e.g. splice enhancers and 
silencers) or by dysregulation of trans-elements such as components of spliceosomes or 
of splicing factors such as serine/arginine-rich [SR] proteins. As an example of cis-acting 
mutations, in gastrointestinal stromal tumors, the KIT gene sometimes undergoes aberrant 
splicing because of deletion of the 3' splice site of intron 10, which leads to the skipping 
of exon 11 (Srebrow and Kornblihtt, 2006). The encoded protein then lacks the internal 
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auto-inhibitory region, which leads to constitutive activation. As an example of 
dysregulation of trans-elements, over-expression of splicing factor SFRS1 
(serine/arginine-rich splicing factor 1) increases the proportion of the exon-3b-containing 
spliceform of the RAC1 (Ras-related C3 botulinum toxin substrate 1) gene (Goncalves et 
al., 2009). This spliceform is hyper-activating and promotes transformation (Singh et al., 
2004). In addition, over expression of splicing factor ASF, serine/arginine-rich proteins 
SRp40 and SRp55 alter the splicing pattern of CD44, a gene having a multiple 
spliceforms (Goncalves et al., 2009). 
1.4. Alternative splicing in gastric cancer 
Alternative splicing can impact almost every classical hallmark of cancer: self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis (Hanahan and Weinberg, 2000). In gastric cancer, 41 aberrant 
splicing events affecting 34 genes have been reported to play roles in gastric 
carcinogenesis, progression, poor prognosis and drug resistance (Table 3 and Table 4). 
Findings of in vivo assays carried out on aberrant spliceforms of CD44, KLF6, CD82 and 
FGFR2 demonstrated their roles in initiation or progression in gastric cancer. Limiting 
dilution assays in NOD scid gamma (NSG) mice revealed that a CD44 variant CD44v8-
10 can initiate tumors (Lau et al., 2014). Similarly, FGFR2-C3 transformed cells in nude 
mice exhibited tumorigenic effects (Itoh et al., 1994). The injection of KLF6-SV1 led to 
shorter survival times and larger tumor sizes in tumor-bearing mice (Chen et al., 2011). A 
CD82 variant lacking exon 7 exhibited a larger tumor volume in vivo (Lee et al., 2003). 
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The possible functional changes of CD44, KLF6, CD82, FGFR2, SPP1, TRIM31, HER2, 
BIRC5, PRKACB, and MST1R variants have been studied in vitro (Table 3 and Table 4). 
The proteins encoded by aberrant splice variants of CD44, KLF6, CD82, FGFR2, SPP1, 
TRIM31, HER2, BIRC5, PRKACB, MST1R, GSDMB, NEILI, MYH, and ANGPT2 have 
been detected by Western Blot or immunoprecipitation methods (Table 3 and Table 4). 
The presence of particular splice variants of GSDMB (Carl-McGrath et al., 2008), TERT 
(Xu et al., 2009) and BIRC5 (Meng et al., 2004) in gastric tumors have been validated by 
RT-PCR. They were found statistically correlated with the incidence of tumors or pre-
cancer lesions. In addition, CD44 variants have been proven to correlate with a poor 
survival rate (CD44v8-10, CD44v5) (Oertl et al., 2005; Shibuya et al., 1998) and lymph 
node involvement (CD44v5, CD44v6) (Oertl et al., 2005; Wang et al., 2006). Other 
alternative splicing events reported in gastric cancer were validated in primary gastric 
tumors or cancer cell lines by RT-PCR.
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Table 3 Aberrant alternative splicing in gastric cancer with strong evidence for biological function 
Abbreviations used in the table: GC=Gastric cancer; Incl.=inclusion of; Excl.=exclusion of; Ex=exon; WT= wild type; TNM 




Proposed consequence Observed Reference Evidence 
CD44 Incl. variable 
Ex 8-10 
The cancer-associated spliceform 
correlates with poor survival rate, the 
number of estimated gastric cancer stem 
cells and can initiate tumors 




Cell proliferation in primary 
gastric cancer cells GC38-adh 
over expression CD44v; 
limiting dilution assay in 
NSG mice 
KLF6 Excl. 154nt 





The cancer-associated spliceform 
promotes proliferation, cell motility, and 







Western Blot, siRNA 
accompany with cell growth 
assay; colony formation; 
migration and invasion assay 
as well as apoptosis assay; 
Caspase activity assayed; 
xenografts 
CD82 Excl. Ex 7 The cancer-associated spliceform 
correlates with poor prognosis, increases 
adhesion to fibronection and in vitro 
motility and invasive potential induced 
by fibronectin and collagen IV; It does 
not co-localized with E-cadherin as wt 
CD82 did and has a weaker interaction 
with Integrin α3β1; It did not affect the 
morphological shape of cells as WT did; 
It lost the capability of suppressing tumor 








proliferation assay; cell 
invasion assay and cell 
adhesion assay in CT-26 







Proposed consequence Observed Reference Evidence 





The cancer-associated spliceform lacks a 
putative phospholipase site, and thus has 
lower autophosphorylation activity. It 
promotes cellular invasion, transforming 










Itoh et al., 
1994) 
Western Blot; colony assay in 




Incl. Ex IIIb 








Spliceform ‘B’ is cancer associated. 
However, both spliceforms inhibit 
proliferation and invasion in some cell 
lines. Spliceform ‘B’ inhibits 
proliferation and invasion in WRO and 
TPC-1 cell lines, but while promotes 
proliferation and invasion in NIH-3T3 
cells. Spliceform ‘B” reduces tumor 
volume of WRO-cell xenografts less than 
spliceform ‘C’. Spliceform ‘B’ promotes 
growth of NIH-3T3 xenografts more than 
spliceform ‘C’. 
Spliceform ‘B’ 








‘C’ in stromal 
fibroblasts. 
 (Guo et 
al., 2012; 
Shin et al., 
2000) 
Proliferation assay; invasion 
assay; xenografts 
SPP1 Incl. of all 
exons 
The cancer-associated spliceform 
promotes cell proliferation of GC 
Gastric cancer, 
cell line GES-1 
(Tang et 
al., 2013) 
Western Blot; cell 
proliferation, cell apoptosis; 
cell migration, cell invasion; 
xenografts  
Excl. Ex 5 The cancer-associated spliceform 
correlates with larger tumor size, deeper 
local invasion and advanced TNM stage; 
It promotes cell proliferation of GC, GC 
cell survival and increased in vivo 










Western Blot; cell 
proliferation, cell apoptosis; 







Proposed consequence Observed Reference Evidence 
Excl. Ex 4 The cancer-associated spliceform 
correlates with lymph node metastasis, 
deeper local invasion and advanced 
TNM stage; It promotes cell proliferation 
of GC, GC cell migration and invasion; It 










Western Blot; cell 
proliferation, cell apoptosis; 




only Incl. Ex 
1 to 4 
(Normal 
associated) 
The normal associated spliceform 
inhibits growth factor mediated tumor 
cell proliferation 
Cell line 





Cell proliferation assay and 
colony assay in MKN7 
BIRC5 Excl. Exon 
3, Incl. Ex 
2B 
The cancer-associated spliceform lost its 
anti-apoptotic potential, inversely 
correlated to the advanced stage, 
undifferentiated tumor and deep tumor 
invasion. It generates more anti-apoptotic 
isotope of BIRC5 and evades the cell 
cycle-specific degradation by the 
ubiquitin proteasome pathway, inhibits 


















2B Incl. in 61/77, exon 3 
skipping in 50/77. 
transfection of constructs in 
HepG2 and cell viability 
assay 
PRKACB Incl. early Ex 
1 
The cancer-associated spliceform 
promotes proliferation and colony 
formation 
Predominantly 




siRNA knock down plus 
colony formation assay; cell 
proliferation assay in cell 






Proposed consequence Observed Reference Evidence 
CD44 Incl. variable 
Ex 5 
The cancer-associated spliceform 
correlates with poor prognosis, a worse 
N tumor stage, blood vessel invasion and 








Adhesion of MKN45 to 
HUVEC monolayer after 
blocked by CD44 variants 
antibody 
Incl. variable 
Ex 4, Incl. 
variable Ex 7 
The cancer-associated spliceform 





Adhesion of MKN45 to 
HUVEC monolayer after 
blocked by CD44 variants 
antibody 
ANGPT2 Excl. 96-148 
AA 
The cancer-associated spliceform is a 
secreted glycosylated dimeric protein and 
binds to the Tie2 receptor as an 
antagonist of Ang-1 induced 
phosphorylation. Role in gastric cancer 
requires further investigation 




Western in COS-7; 
Phosphorylation Assays of 
Tie2 Receptor in HUVEC. In 
Vitro Binding Assay  
MST1R Excl. Ex 11 The cancer-associated spliceform 
segregates in the intracellular 
compartment, oligomerizes by stable 
intermolecular disulﬁde bonds, and 
displays constitutive tyrosine 
phosphorylation. The cells expressing 













Table 4 Aberrant alternative splicing in gastric cancer with strong technical validation 
Abbreviations used in the table: GC=Gastric cancer; Incl.= inclusion of; Excl.= exclusion of; Ex=exon; ext=extended; 
WT=wild type; TNM stage=size of the primary tumor (T), lymph nodes (N) spread nearby, presence of metastasis (M) . 
Gene Event Proposed consequence Observed Ref 
ALDOC Incl. Ex 1a, 5a, Excl. 
Ex 1, 5-9 
The cancer-associated spliceform can be 
a candidate biomarker for metastasis-
related gastric cancer 
Gastric cancer, cell lines 
AGS, AZ521, SNU1, 
SNU16, KATOIII, MKN74 
(Hatakeyama 
et al., 2011) 
Incl. Ex 1a, 1a-ext, 
5a, Excl. Ex 1, and 5-
9 
The cancer-associated spliceform can be 
candidate biomarker for metastasis-
related gastric cancer 
Gastric cancer, cell lines 
MKN45P, SNU1, SNU16, 
KATOIII, Hs746t 
(Hatakeyama 
et al., 2011) 
REG3A Alternative use of 5' 
of Ex 2 
not clear Gastric cancer  (Itoh et al., 
1995) 
NEIL1 Mutation 936G>A 
leads to retention of 
intones 10 
The cancer-associated spliceform lost the 
localization signal and mislocalization 
due to the early stop codon led by intron 
retention which replaces C-terminal 78 
AA with 25 unrelated AA 




MYH Mutation 892-2A>G 
leads to retention of  
intron 10 
The cancer-associated spliceform 
encoded a truncated protein lacking a 
nuclear localization signal and protein 
mislocalization within the cell (in 
cytoplasm instead of nucleus) due to the 
intron retention causing early stop codon 
Nine GC patient with 
IVS10-2A>G 
(Tao et al., 
2004) 
WNT2B Incl. Ex 3-7 The cancer-associated spliceform does 
not contain the N-terminal hydrophobic 
signal peptide, positively regulates WNT-
β-catenin-TCF signaling pathway, and 




Katoh et al., 
2000; Katoh 
et al., 2001) 
CD44 Incl. variable Ex 6 The cancer-associated spliceform 
correlates with lymph node metastasis 
and tumor burden 
Bone marrow from gastric 
cancer patient 




Gene Event Proposed consequence Observed Ref 
CTSE Excl. Ex 7 The cancer-associated spliceform 
undergoes protein structure change 
caused by a frame shift, includes two 
domains (4 for WT), and the active site is 
oriented in the vertical direction 
(horizontal for WT) 
Cell line AGS, KATO-III (Tatnell et al., 
2003) 
ERBB3 Retain part of intron 
between Ex D and Ex 
U, leads to 3' 
truncated transcript 
not clear Gastric cancer, cell line 
MKN45 
(Katoh et al., 
1993) 
CCKBR Retains intron 4 The cancer-associated form may have 
unknown physiological functions in 
gastric epithelial cells 
Gastric carcinoma and cell 
line SGC-7901 
(Zhou et al., 
2004) 
BIRC5 Incl. Ex 3b derived 
from 165bp portion 
of intron 3 
Retention of portion of intron causes 
early stop codon and encodes truncated 
120AA protein of the tumor-associated 
spliceform. It lacks tubulin-interacting C-
terminal coiled-coil region, and may not 
be associated with G2/M phase 
Gastric adenocarcinoma, 
KATO-III, TMK1, MKN74, 
MKN45 
(Badran et al., 
2004) 
TACC1 Excl. Ex 1-3, Incl. Ex 
1a,4a; Excl. Ex1,2, 
Incl. Ex 4a 
The cancer-associated spliceform disrupts 
nuclear localization signals, and might 
contribute to centrosome malfunction, 
such as formation of large, highly 
ordered protein aggregates around the 
centrosome, and an increase in the 
number and/or length of centrosome 
microtubules 
Gastric cancer  (Line et al., 
2002) 
FUT1 Incl. Ex1a (regulated 
by alternative 5' 
promoter) 
not clear MKN74 (Koda et al., 
1997) 
CDH1 Excl. Ex 9, retain 
intron 9 
not clear HSC-44, HSC-44As3 (Furuta et al., 
2012) 




Gene Event Proposed consequence Observed Ref 
TERT Incl. 36bp of Ex 6, 7-
8 
The proportion of the cancer-associated 
spliceform increased in gastric cancer 
versus normal mucosa and pre-cancer 
lesions 
Pre- Gastric cancer lesion, 
Gastric cancer 
(Xu et al., 
2009) 
ING4 Excl. Ex 2,3; Excl. 
Ex 3 
The cancer-associated spliceform leads to 
mislocalization of p53 and/or 
HAT/HDAC complexes, initiation and 
progression of stomach adenocarcinoma 
Gastric cancer , poorly 
differentiated cell line 
MGC-803, 
(Li et al., 
2009a) 
FAS Shorter than normal 
full transcript 
The cancer-associated spliceform is 
soluble, blocks the function of WT FAS 
(induces cell death by apoptosis in 
susceptible cells) 
Primary tumor of gastric 
cancer 
(Lee et al., 
1998) 
GSDMB Excl. Ex 5; Excl. Ex 
6; Excl. Ex 5-6 
The proportion of aberrant transcripts 
increases as cancer progresses 







CDCA1 Incl. Ex1a, 2; Incl. 
Ex1a, 1b and Ex 2 
The cancer-associated spliceform may 
play a role in chromosomal 
missegregation and carcinogenesis, 
which still needs to be elucidated 
Gastric cancer cell lines 




TRIM31 Excl. 3' cds region 
coding a coiled-
coiled domain (β). 
Full length (α) up-
regulated 
The cancer-associated spliceform may 
not localize to mitochondrial 
Gastric cancer  (Sugiura and 
Miyamoto, 
2008) 
MPRIP Incl. Ex 22, Ex 24, 
Excl. Ex 23 
As MPRIP is an essential regulatory 
component of the RhoA signaling 
pathway, the cancer-associated 
spliceform may be implicated in human 









Gene Event Proposed consequence Observed Ref 
HYAL2 Incl. Ex 2, Ex 3, 
Excl. Ex 1 
The cancer-associated spliceform may 
promote tumor growth and metastasis; a 
discernible effect due to HYAL2 has not 
yet been reported 
Cell lines MKN7, IM95, 





replaces the Ex 1a of 
p16INK4a with Ex 
1b 
The cancer-associated spliceform is 
possibly involved in diffuse type gastric 
cancer 
Cell lines MKN74, NUGC-
3,MKN7,MKN28 
(Iida et al., 
2000) 
MUTYH Excl. the 64bp of 5' 
of Ex 3(γ); retain 
17bp of 5' of 
intron1(IS2) 
The cancer-associated spliceform 
encodes truncated proteins, presumed not 
to produce functioning proteins, and 
connected to gastric tumorigenesis or 
cancer development 




TYMS Excl. Ex 2,3 The cancer-associated spliceform 
influences clinical outcomes following 
treatment with 5-FU 







The cancer-associated spliceform reveals 
a binding site for POU5F1 transcription 
factors within the promoter region;  
implicated in the reactivation of silenced 
genes 
Diffuse type gastric cancer (Katoh, 2007) 
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These aberrant splicing events include exon skipping, intron retention, alternative 
transcription start site, alternative use of 5' exon, and early stop truncation. The resulting 
changes in protein products affect major cancer signaling pathways involved in cell 
growth, apoptosis, cell differentiation, and cell invasion (Table 3 and Table 4). Signaling 
pathways affected include the fibroblast growth factor (FGF) pathway, the Wnt pathway, 
the MAPK pathway, the Hedgehog pathway, the p53 pathway, and the ERBB pathway.  
1.4.1. FGFR2 in the FGF signaling pathway 
 
Figure 5 Fibroblast growth factor signaling network in gastrointestinal tract. 
(reproduced with permission (Katoh, 2006)) 
The FGF receptor FGFR2 undergoes alternative splicing. One spliceform that includes 
exon C3 has been reported to be over expressed in gastric cancer cell line KatoIII 
22 
 
compare to normal (Ishii et al., 1995; Itoh et al., 1994). The encoded protein, which is 
truncated, lacks a putative phospholipase site and thus has lower auto-phosphorylation 
activity (Ishii et al., 1995; Itoh et al., 1994). This spliceform has greater transforming 
activity and higher mitogenic potential (Ishii et al., 1995; Itoh et al., 1994). Another 
spliceform that includes exon 3b has been reported to be over expressed in diffuse type 
gastric cancer and correlates with poorly differentiated gastric cancer (Shin et al., 2000). 
This spliceform also stimulates proliferation in gastric cancer (Katoh, 2006) and 
effectively mediates cellular invasion(Shin et al., 2000). Biological changes of FGFR2 
were mediated through the FGF pathway (Figure 5) that involves 23 FGF-family genes 
and plays an important role in cell growth and differentiation via the RAS/MAPK 
signaling cascade (Ishii et al., 1995; Shin et al., 2000). The FGF pathway also determines 
cell survival and cell fate via the PI3K/AKT signaling cascade (Ishii et al., 1995; Shin et 
al., 2000). It can be activated in response to H. pylori infection (Ishii et al., 1995; Shin et 
al., 2000).  
1.4.2. PRKACB and other known gastric cancer related alternative spliced genes in 
the same pathways 
Protein Kinase, CAMP-Dependent, Catalytic, Beta (PRKACB ) spliceform that 
predominantly includes exon 1 was found to be expressed in 32 gastric cancer tumors and 
promotes proliferation and colony formation (Furuta et al., 2012). PRKACB is a 
signaling molecule that mediates cAMP-dependent signaling triggered by receptor 
binding to GPCRs and is involved in the MAPK pathway, Wnt pathway and Hedgehog 
pathway. The MAPK signaling pathway regulates cell growth and differentiation (Ishii et 
al., 1995; Shin et al., 2000). In the same pathway, the Fas cell surface death receptor 
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(FAS) gene also undergoes aberrant splicing. The shorter spliceform encodes a soluble 
protein and has been detected in gastric tumors. This soluble FAS spliceform suppresses 
normal functions of FAS, including induction of cell death by apoptosis (Lee et al., 1998). 
Wnt pathway is known to be involved in oncogenesis. One line of evidence shows that 
aberrant Wnt pathway can initiate development of polyps in colonic epithelia (Taketo, 
2006). It is also reported to can repress downstream transcription factors in the Notch 
signaling pathway and thus disrupt cell fate determination (Taketo, 2006). The Wnt 
pathway can also activate downstream JNK and APC/β-catenin pathways that regulate 
tumor size and number (Taketo, 2006). Wnt pathway activation was found in 30%-50% 
of gastric tumors. It can promote epithelial proliferation (Katoh, 2006) through FGF 
signaling, induce preneoplastic lesions and suppress epithelial differentiation by 
maintaining the undifferentiated status of stem cells (Oshima and Oshima, 2010). In this 
pathway, two other genes, WNT2B and CTNNB1 are known to undergo aberrant splicing. 
A spliceform of WNT2B that includes exons 3 through7 has been detected in gastric 
tumors and the gastric cancer cell lines MKN28, MKN45, and MKN74 (Katoh, 2001; 
Katoh et al., 2000; Katoh et al., 2001). The encoded protein of this splice form does not 
contain the N-terminal hydrophobic signal peptide (Katoh, 2001; Katoh et al., 2000; 
Katoh et al., 2001). It positively regulates the WNT-β-catenin-TCF (T cell factor) 
signaling pathway and may lead to carcinogenesis (Katoh, 2001; Katoh et al., 2000; 
Katoh et al., 2001). One CTNNB1 spliceform that lacks exon 3 has been detected in 
gastric cancer cell lines even though its functional consequences remain unclear (Furuta 
et al., 2012). 
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The Hedgehog pathway is an oncogenic pathway that promotes epithelial proliferation in 
the stomach through cell cycle regulation (Katoh and Katoh, 2005, 2006). Hedgehog-
pathway activation is frequently observed in gastric cancer (Katoh and Katoh, 2005). The 
Hedgehog family member Sonic Hedgehog (SHH) regulates differentiation or maturation 
of parietal cells by transducing EGF-AKT signals (Katoh and Katoh, 2005). Its activation 
helps restitution of gastric mucosa damage caused by H. pylori (Katoh and Katoh, 2005). 
In this pathway, WNT2B and PRKACB undergo aberrant splicing as discussed in the 
subsection that describes PRKACB and other known alternatively spliced genes reported 
in gastric cancer. 
1.4.3. CD82 in the p53 pathway 
One CD82 spliceform that lacks exon 7 has been detected in metastatic gastric cancer. 
This spliceform cannot co-localize with E-cadherin due to the absence of a part of the 
second extracellular loop and part of the fourth transmembrane region (Lee et al., 2003). 
Thus this alternative splicing does not affect cell morphology of cell as usual spliceform 
as CD82. But it exhibited increased adhesion to fibronectin, in vitro motility and invasive 
potential (Lee et al., 2003). Expression of this particular spliceform is associated with 
poor prognosis, and this spliceform does not suppress tumor growth (Lee et al., 2003). 
CD82 is a metastasis suppressor gene and a membrane glycoprotein. It is known to be 
activated by p53. The p53 pathway responds to stress by triggering cell cycle arrest or 
apoptosis (Harris and Levine, 2005). In this pathway, CD82, CDKN2A and FAS undergo 
aberrant splicing. A spliceform of CDKN2A that includes exon 1b instead of exon 1a has 
been detected in gastric cancer cell lines and is involved in diffuse gastric cancer (Iida et 
al., 2000).  
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From gastric cancer associated spliced genes, we notice that known genes tend to be 
enriched in oncogenic or cancer progress pathways.  Genes belonging to two different 
pathways maybe converge to a common pathway by connecting hub gene (e.g. PRKACB). 
Thus, by detecting more gastric cancer associated spliced genes, I speculate we can 
identify a set of interconnected cancer related pathways. Furthermore, these pathways 
may connect to each other by hub genes. 
1.4.4. Other examples of AS in gastric cancer 
Apart from well-known cancer driver genes, the effects of altered splicing in gastric 
carcinogenesis have been described for a few other genes. One well-studied example is, 
the splice variants of the CD44 gene which are known to contribute to tumorigenesis 
(Ponta et al., 2003). For example, the spliceform CD44v8-v10 promotes gastric 
tumorigenesis via increased glutathione synthesis and therefore resistance to oxidative 
stress (Ishimoto et al., 2011). The spliceform CD44v5 is expressed preferentially in 
poorly differentiated tumors and metastatic lymph nodes and correlates with shorter 
survival (da Cunha et al., 2010). The spliceform CD44v6-v14 promotes cell growth in 
gastric cancer cell lines (Takeo et al., 2009). 
Other examples of the effects of alternatively spliced genes in gastric cancer include the 
genes BIRC5 (baculoviral IAP repeat containing 5) and MST1R (macrophage stimulating 
1 receptor [c-met-related tyrosine kinase], also known as RON). One BIRC5 spliceform 
inhibits growth and is down-regulated in epithelial carcinomas, including gastric cancer 
(Venables, 2006); the presence of the growth-inhibitory spliceform of BIRC5 correlates 
with a better prognosis in late-stage and metastatic gastric carcinomas (Venables, 2006). 
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Similarly, a spliceform of MST1R that lacks exon 11 is identified in gastric cancer. The 
encoded protein lacks 49 amino acids of the β-chain region and thus cannot be cleaved. 
The resulting protein is constitutively activated, which has been observed to increase cell 
motility in vitro (Srebrow and Kornblihtt, 2006). 
1.5. Techniques and methods for genome-wide assessment of alternative splicing 
Exon arrays (Okoniewski and Miller, 2008), exon junction arrays (Johnson et al., 2003), 
PCR (Klinck et al., 2008), and deep RNA-sequencing (Mortazavi et al., 2008) have been 
used to study the AS in human tissues and cells.  
1.5.1. Exon array 
A single exon array interrogates each potential exon in the transcriptome with one probe 
set (Figure 6). By contrast, traditional microarrays consider transcription at the level of 
entire genes (Chen et al., 2005) and do not distinguish between different spliceforms. On 
the Affymetrix Human Exon 1.0 ST Array, 5,362,207 features (hybridization probes) are 
grouped into 1.4 million "probe sets" interrogating one million "exon clusters" 
(collections of overlapping exons). Table 5 enumerates the algorithms and software that 
have been developed to analyze these data. Among these methods, FIRMA (Finding 
Isoforms using Robust Multichip Analysis), a method for the detection of alternative 





Figure 6 Analyses of alternative splicing with exon arrays. 
a) Exon arrays can be used for large-scale identification of splicing differences between 
two RNA populations. b) The predicted splicing events are validated by RT-PCR. 





Table 5 Algorithms for exon array data 
Short name Full name Validation rate 
by RT-PCR 
Reference 
ARH Alternative splicing 
Robust prediction 
method based on 
entropy 
NA (Rasche and Herwig, 2010) 
REMAS REgression Method for 
AS detection 
4 out of top 10 (Zheng et al., 2009) 
LIMMA Linear Models for 
Microarray Analysis 
NA (Shah and Pallas, 2009) 
MADS Microarray Analysis of 
Differential Splicing 
27 out of 30 
novel 
(Xing et al., 2008) 
FIRMA Finding Isoforms using 
Robust Multichip 
Analysis 
16 out of 36 (Purdom et al., 2008) 
ANOSVA ANalysis Of Splice 
VAriation 
NA (Cline et al., 2005) 
MiDAS Microarray Detection of 
Differential Splicing 
NA (Affymetrix, 2005) 
PAC PAttern-based 
Correlation 
NA (Affymetrix, 2005) 
SI Splicing Index NA (Srinivasan et al., 2005) 
FIRMA uses general linear model. It includes the possibility of alternative splicing or 
different levels of expression per exon, chip effect, probe set effect, background-
correction, interaction between exon and sample, assuming a zero- sum constraint for 
these parameters. The FIRMA score can be calculated by arom.affymetrix software 
(Purdom et al., 2008) through the following background adjustment, summarization of 
the entire transcript and FIRMA score calculation. More details will be described in 
chapter 3 
1.5.2. RNA-seq 
RNA-seq is a new approach for assessing transcript abundance and splice form and was 
used in my project for several reasons: 1) This technique can provide a digital measure of 
known and previously unknown genes' transcripts' presence and prevalence; 2) It can 
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detect RNA splicing directly, and can suggest new and revised gene models; 3) compared 
with exon arrays, RNA-Seq has lower background noise. Many software packages have 
been developed to analyze RNA-Seq data for identification of novel transcripts and 
estimation of transcript abundance (Table 6 and 7). Among these software packages, 
TopHat (Trapnell et al., 2009) is an efficient algorithm to align short paired-end reads to 
a reference genome that does not rely entirely on known splice junction. TopHat first 
aligns all reads to a reference genome by using the Bowtie aligner (Langmead et al., 
2009). TopHat then generates islands of contiguous sequence by assembling mapped 
reads. TopHat subsequently lists all GT-AG splice sites in sequence islands and 
constructs all possible splice junction sequences, and then aligns as-yet unmapped reads 
to the splice-junction sequences. STAR (Dobin et al., 2013) is an unbiased strategy to 
align short paired-end reads to reference genome that can detect de novo non-canonical 
splice junctions . First, STAR searches the longest substring that start from the first base 
of reads that can be mapped to reference genome via uncompressed suffix arrays 
(Manber and Myers, 1990). Then, STAR searches the unmapped portions of reads. 
Subsequently, STAR clusters previously mapped split reads based on proximity to built 
putative linear transcription model. 
MISO is a software package that was developed to detect alternative splicing (Katz et al., 
2010b). On the basis of the mapping results, MISO tries to assign each read pair to the 
spliceform with the higher posterior probability of having generated the read pair based 
on the fragment size distribution and the mapped positions of the reads. Following that, 
MISO calculates the relative expression of each isoform via dividing number of 
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fragments mapped to isoform A by the total number of fragments mapped to either 
isoform A or B (Katz et al., 2010b).  
Table 6 Short-read aligners 
Name Description Reference 
Bfast Blat-like fast accurate search tool (Homer et al., 2009) 
Bowtie Ultrafast, memory-efficient short read aligner, Uses a 
Burrows-Wheeler-Transformed (BWT) index 
(Langmead et al., 2009) 
BWA BWT short read aligner (Li and Durbin, 2009) 




MAQ Mapping and Assembly with Qualities. Particularly 
designed for Illumina 
(Li and Durbin, 2009) 
SOAP2 Short Oligonucleotide Alignment Program, Short read 
aligner for efficient gapped and unmapped alignment 
(Li et al., 2009b) 
TopHat Fast splice junction mapper for RNA-Seq reads, built 
on Bowtie. Identifies splice junctions between exons 












































Qpalma Spliced read 
mapper 
Y Integrated Predicted from 
transcripts 











RPKM (Jiang and 
Wong, 
2009) 
Cufflinks Existing and 
novel gene  
quantitation 







SOLAS Existing gene 
model  







N TopHat From existing 
models 
Proportion (Katz et 
al., 2010b) 
1.6. Aims of this thesis 
Although some gastric-cancer-specific spliceforms have been identified and studied in 
detail, studies of alternative splicing in gastric cancer have focused on the functions of a 
relatively small number of specific genes. Thus, a broad and systematic study of gastric 
cancer transcriptomes may identify additional cancer related perturbations of splicing and 
delineate the altered functions of cancer-related spliceforms. The recent development of 
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RNA sequencing (RNA-seq) promises to provide a powerful tool for unbiased 
assessment of alternative splicing in gastric cancer with high efficiency and resolution 
(Ozsolak and Milos, 2011; Wang and Cooper, 2007). 
The main goal of this thesis is to use RNA-seq to comprehensively survey alternative 
splicing in primary gastric adenocarcinoma tumors and in gastric adenocarcinoma cell 
lines. Subsidiary goals include in-silico analysis of the functions of genes with gastric-
cancer-associated spliceforms, technical confirmation of the best-supported tumor-
associated spliceforms using RT-PCR, and investigation of the generality of possible 
cancer-specific spliceforms in an independent panel of matched tumor and normal 
samples. 
In addition, this thesis also aims to survey the capabilities and limitations of different 
techniques and algorithms for AS identification. Finally, this thesis applies the analysis of 
alternative splicing to the study of splicing aberration in upper urothelial cancer caused 
by an herbal remedy that often mutates the 3' splice-site sequence from CAG to CTG 




2. Chapter 2 Global analysis of alternative splicing in gastric cancer 
2.1. Materials and Methods 
2.1.1. Primary tissues and cell lines 
The work in this subsection was carried out by laboratory members other than the 
candidate and is provided as necessary background information to interpret the results. 
Primary gastric adenocarcinoma tumor tissues, matched normal tissue samples, and 
clinical information were obtained from Singapore Health Services (SingHealth) and the 
National University Hospital System (NUHS) tissue repositories, with signed informed 
consent and approvals from the respective institutional research ethics review committees. 
Matched normal samples were taken from non-malignant mucosa adjacent to the tumor. 
Sup Table 2 provides clinical information on these 17 tumor normal pairs. All samples 
were from Singaporean patients, and pathologists here rely entirely on the Lauren 
classification. Sup Table 3 provides information on the characteristics and sources of the 
10 gastric cancer cell lines studied.  
2.1.2. RNA extraction, library preparation, and RNA sequencing 
The work in this subsection was carried out by laboratory members other than the 
candidate and is provided as necessary background information to interpret the results. 
Total RNA was extracted from frozen tissues or cell pellets using the Qiagen RNeasy 
mini kit. Samples for RNA-seq were prepared according to the TruSeq RNA Sample Prep 
Guide (Illumina). Briefly, 2μg of total RNA were extracted and subject to polyA 
selection. The selected mRNAs were fragmented by temperature with a target size range 
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of 200 to 300bp and then converted to cDNA using random primers and reverse 
transcriptase (SuperScript II, Invitrogen). After purification and ligation of adapters, the 
sequencing libraries were enriched using 15 cycles of PCR using adapter-specific primers. 
Sequencing libraries from primary tissues and cell lines were analyzed on an Illumina 
Genome Analyzer II or an Illumina HiSeq with coverage and read lengths as indicated in 
Sup Table 4. 
2.1.3. Read mapping 
Reads were first aligned to the Homo sapiens reference genome (hg19) using TopHat 
v1.2 (Hubbard et al., 2002). TopHat then attempted to map as-yet unmapped reads to 
potential splice junctions that were either (1) present in the Ensembl (version 60) 
transcript annotation (Hubbard et al., 2002) or (2) suggested by “expression islands”—i.e. 
clusters of reads that were not within annotated transcripts. Analysis of RNA sequencing 
quality was performed with RNA-SeQC v1.7 (DeLuca et al., 2012) using the default 
options, with results as shown in Sup Table 4. The results of the quality analysis indicate 
that the majority of reads fall in the intragenic region and that most genes can be detected. 
2.1.4. Creating customized alternative splicing events for MISO 
I created a customized list of alternative splicing events (ASEs) for MISO by comparing, 
for each gene, all pairs of Ensembl-annotated transcripts from that gene to identify 
potentially skipped or mutually exclusive exons. MISO considers an ASE to consist of 
either a skipped exon or a pair of mutually exclusive exons plus the immediately flanking 
exons. The method works as follows: (1) Each pair of transcripts drawn from a set of 
gene transcripts (Figure 7a) is aligned according to the transcripts’ genomic coordinates 
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(Figure 7b). (2) The first common exon of the two transcripts is marked as the starting 
exon (Figure 7b). (3) Exons included in one transcript and not in the other are identified 
using a sliding approach. For example, when one pointer moves to a differentially 
included exon (Figure 7d, blued arrow) in transcript 2, the pointer of transcript 1 moves 
to the next common exon (Figure 7d, light-blue arrow). (4) The pointer of transcript 2 
moves one exon back and indicates the upstream flanking exon of the ASE while the 
pointer of transcript 1 indicates the downstream flanking exon of the ASE (Figure 7e). In 
addition, exons between these two flanking exons were treated as exons being involved in 
the ASE (Figure 7e, red rectangle).  
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Figure 7 Procedures of creating customized ASEs. 
a) Two transcripts drawn from a set of gene transcripts are in the red rectangle. b,c) The two 
transcripts are aligned according to their genomic coordinates, and common exons are indicated 
by blue arrows. d) Differentially included exon in transcript 2 is indicated by the blue arrow; the 
following exon common to both transcripts is indicated by a light blue arrow. e) Two blue arrows 
indicate exons flanking the ASE, and red rectangle contains all exons within the ASE. 
2.1.5. Estimating relative abundance of alternative spliceforms 
The aligned read files (BAM files) produced by TopHat were processed by the Mixture 
of Isoforms (MISO) software version 0.50 (Katz et al., 2010a) according to the protocol 
for paired end reads. MISO considers an “alternative splicing event” (ASE) to consist of 
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either a skipped exon or a pair of mutually exclusive exons plus the immediately flanking 
exons. The MISO analysis relied on MISO-provided ASE annotation files and a 
customized list of ASEs created as described in Section 2.1.4 to describe possible 
alternative RNA processing. MISO estimates ASE abundance as follows. For skipped-
exon ASEs, “isoform A” includes the 5' flanking exon, the optionally skipped exon, and 
the 3' flanking exon. “Isoform B” includes only the 5' and 3' exons. For mutually-
exclusive-exon ASEs, “isoform A” includes the 5' flanking exon, the first mutually 
exclusive exon, and the 3' exon; “isoform B” includes the 5' exon, the second mutually 
exclusive exon, and the 3' exon. MISO tries to assign each read pair to the spliceform 
with the higher posterior probability of having generated the read pair based on the 
fragment size distribution and the mapped positions of the reads. (Katz et al., 2010a). The 
relative expression of isoform A in the mixture of isoforms A and B is expressed as 
“percentage spliced in”, denoted ψ. This is the number of fragments (i.e., read pairs) 
mapped to isoform A divided by the total number of fragments mapped to either isoform 
A or B. I calculated ψ for all possible ASEs for each sample. I restricted analysis to ASEs 
that were represented by ≥ 20 read pairs. 
2.1.6. Detection and analysis of cancer-associated ASEs 
To identify possible tumor-associated spliceforms, I applied filters to the possible ASEs 





Figure 8 Analytical workflow for identifying likely tumor-associated or 
predominantly tumor-specific alternative splicing events (ASEs). 
Filters 1, 2, and 3 are described in the text. a) Refers to ASEs and genes that were 
analyzed further because of potential biological interest, as discussed in the main text. b) 
Refers to the literature-based evidence that the ASE alters the biochemical or cellular 
function of the genes product. c) Indicates the results of RT-PCR testing of predicted 
ASEs. 




Table 8 Definitions used in Filters 1, 2, and 3 
Notation Meaning 
BF()  The MISO Bayes factor (Katz et al., 2010a) 
||S|| The size of set S 
& Logical ‘and’ 
Ψs,x The proportion of isoform s in sample x 
DΨs,x The density of isoform s in group x at Ψ 
Filter 1 ensures that one of the isoforms, sa, in the ASE is more abundant in at least two 
tumor, Ti, compared to the matched normal sample, Ni. This filter was set for minimal 
recurrence. 
 
Filter 2 is designed to require additional support for the importance of the ASE in gastric 
cancer by ensuring that sa is systematically more abundant in tumor samples than in the 
matched normal samples (paired Wilcoxon test, p < 0.05). 
Filter 1 
For sa in each tumor-normal pair, <Ti, Ni> do: 
 Let T = { i | Ψs,Ti - Ψs,Ni >= 0.2 & BF(sa, Ti, Ni) >= 100} 
 If ||T|| < 2 then discard sa 






Filter 3 is independent of Filter 2 (Figure 8) and is designed to require additional 
evidence for cancer specificity by ensuring that (i) the candidate tumor-associated 
isoform, sa, is rare in most samples of non-malignant gastric mucosa, (ii) in a significant 
proportion of tumors, sa is higher in the tumors than all normal, and (iii) in at least one 
tumor, sa is significantly higher than in all non-malignant samples.  
Filter 2 
For sa, do 
 Paired Wilcoxon test on Ψs,T - Ψs,N 
 if not (p value < 0.05) then discard sa 
 Else sa passes 
End for 
sa fails  
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Finally, all candidate spliceforms are sorted based on the following values: 
(1) ∑ (DΨ𝑠,𝑇  −  DΨ𝑠,𝑁)Ψ𝑠,𝑒𝑛𝑑 Ψ𝑠,𝑠𝑡𝑎𝑟𝑡 , (2) Ψs,N95%, (3) min (ΨS,Tpeak ,ΨS,T95% ) −ΨS,N95% . 
Filter 3 (3 parts) 
 
For sa, do 
 
Filter 3.1 (Requires that sa is rare in most samples of non-malignant gastric mucosa.) 
  
if not Ψs,N95% < 0.3 then discard sa 
 
Filter 3.2 (Requires that sa is higher in a significant proportion of tumors than in all normal 
samples.) 
 
do density comparison on (DΨs,T, DΨs,N) as in Figure 9  
 
if  ∃Ψ𝑠,𝑐𝑟𝑜𝑠𝑠 𝑝𝑜𝑖𝑛𝑡|DΨ𝑠,𝑇   =  DΨ𝑠,𝑁 
Ψs,start = max (Ψs,N95%, Ψs, cross point) 
Ψs,end = max (DΨ𝑠,𝑇) 
 if not p-value < 0.05 &∑ (DΨ𝑠,𝑇  −  DΨ𝑠,𝑁)Ψ𝑠,𝑒𝑛𝑑 Ψ𝑠,𝑠𝑡𝑎𝑟𝑡  > 0 then discard s 
 
Filter 3.3 (Requires that sa is significantly higher than all non-malignant samples.) 
 
if not  min (ΨS,Tpeak ,ΨS,T95% ) −ΨS,N95%  > 0.2 then discard sa 




Figure 9 Density ψ values for an example ASE in all tumor versus all normal. 
The red line represents the density of tumor samples, while the green dotted line 
represents the density of normal samples. The blue vertical lines indicate the intersection 
point of the red line and green dotted line, location where 95% normal density occurs, 
and the peak of tumor density. 
2.1.7. RT-PCR validation of ASEs 
Total RNA was extracted using the RNeasy Mini kit (Qiagen, CA), digested with RNase 
free DNase (RQ1 DNase, Promega), and subsequently purified using an RNeasy Mini kit 
(Qiagen, CA). RNA was used to synthesize cDNA using the SuperScript III First Strand 
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Synthesis System (Invitrogen) with random hexamers according to the manufacturer’s 
instructions. Primers were designed by primer3 (Untergasser et al., 2012) and are shown 
in Sup Table 10. We used GoTaq® Hot Start Polymerase (Promega) to execute PCR 
reactions with the following thermal cycling conditions: initial denaturation at 94ºC for 2 
min, denaturation at 94ºC for 30 seconds, annealing at 58 ºC  for 30 seconds, extension at 
72 ºC for 1 min and final extension at 72 ºC for 5 min, for 39 cycles.  
2.2. Results 
2.2.1. RNA sequencing 
We sequenced and analyzed the transcriptomes of 10 gastric-cancer cell lines and 12 
primary gastric tumors along with matched non-malignant tissues (Sup Tables 4 part A 
and part B). Sup Table 4 details the characteristics of the sequence data. The number of 
read pairs per sample ranged from 6.09 M to 129 M because of sequencing capability of 
GAII and Hiseq2000. After aligning reads to the human genome, the number of read 
pairs per sample that mapped to unique sites in the genome ranged from 5.52 M to 92.8M 
due to the sequencing coverage difference. At least 94% of read pairs mapped to 
intragenic regions, and 81% mapped to exons. 80% of transcripts had expression levels > 
0.5 FPKM (fragments per Kilobase of exon per million fragments mapped).  
2.2.2. ASE detection and comparison between pairs of samples 
I compared ASEs between every pair of samples in the entire set of 12 tumor and 12 
normal samples. Among ASEs that MISO found to be different between two samples at 
BF > 100, the maximum width of any confidence interval (CI) of ψ was 0.78. 
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Comparison of ASEs with CI > 0.78 vs. ASEs with CI <= 0.78 showed that ASEs with 
large CIs (i.e. CI > 0.78) usually had expression levels (FPKM values) < 0.5 (~80% of 
ASEs, Figure 10a). By contrast, ASEs with CIs < 0.78 usually had expression levels 
(FPKM values) > 0.5 (~90% of ASEs, Figure 10a). In addition, only 2% of ASE 
comparisons with BF > 100 had FPKM values < 0.5 (Figure 10b). ASEs with expression 
levels < 0.5 FPKM likely have too few informative fragments assigned to each 
spliceform to allow accurate estimates of ψ (Figure 11). This is illustrated in Figure 11c, 
the ASE "chr4:170907748:170913460:-@chr4:170923116:170923377:-
@chr4:170924822:170924952:-" contained two spliceforms. This ASE was expressed at 
0.09 FPKM in 980097T and at 2.55 FPKM in 990172T (Figure 11a). The estimated 





Figure 10 Density of FPKM of ASEs. 
a) Density of FPKM of ASEs with CIs > 0.78 and < 0.78. b) Density of FPKM of ASEs 




Figure 11 The effects of ASE expression level on “confidence intervals” (posterior 
distribution) of ψ. 
a) RNA-seq read depths at an ASE in 990172T and 980097T. b) Posterior distribution of 
ψ estimated by MISO. c) Annotation of the ASE. 
2.2.3. Whole transcriptome view of alternative splicing in gastric cancer 
To measure the levels of different spliceforms and identify differentially spliced events 
among samples, I used MISO (Katz et al., 2010b) to calculate ψ for the skipped-exon and 
mutually-exclusive-exon ASEs in the transcripts from each sample. I detected between 
14,103 and 45,120 ASEs per tumor sample and from 6,272 to 43,230 ASEs per normal 
sample (Table 9). The number of ASEs that were detectable in tumor is comparable with 
the number in matched normal in most tumor normal pairs.  The number of ASEs that 
were detectable in both tumor and matched normal tissue ranged from 5,821 to 40,740 
per pair. Such variation usually comes from different sequencing batches and may be 
affected by sequencing coverage (p < 0.05, person correlation test), library preparation 
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and sample. I then proceeded to identify and prioritize possible tumor-associated ASEs 
using the filtering strategy described in Figure 8. The number of ASEs that were 
differentially spliced between tumor and matched-normal pairs at |Δψ| > 0.2 and BF > 
100 ranged from 146 to 1,170 per pair. Such variation may reflect differences in the 
biology of different tumors and in different adjacent tissue samples. This variation may 
also stem from tumor content, as indicated in Figure 12 (p = 0.06, r2=0.366, Pearson 
correlation test). Only a small fraction of detectable ASEs were candidates for tumor-
associated ASEs by the criteria of Filter 1 (Table 9): out of 47,167unique ASEs found in 
both the tumor and normal samples of at least one pair, only 1,397 satisfied Filter 1. The 
number of ASEs that satisfied filter 1 in tumor-normal pairs ranged from 146 to 1,170, 
while only 68 ASEs show difference between normal replicates. Of the 1,397 ASEs 
satisfying Filter 1, 545 also satisfied Filter 2 (Table 9, Sup Table 5). The fraction of ASEs 
detected in both tumor and normal pairs that passed Filters 1 and 2 ranged from 0.21% to 




Figure 12 Correlation between tumor content (x axis) and the number of ASEs with 
|Δψ| > 0.2 and BF > 100 between tumor and matched normal (y axis). 
Shown are 8 tumors for which we had pathologist-estimated tumor content. M, Lauren 
mixed subtype; D, Lauren diffuse subtype; I, Lauren intestinal subtype. 
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Table 9 Number of alternative splicing events detected by MISO 
% ASEs passing filter 1 and 2 was calculated as the number of ASEs that pass Filters 1 and 2 divided by the number of ASEs found in 
both the tumor and normal samples of a pair. 
  
Number of mapped 
read pairs 
(millions)  
Number of alternative splicing events (ASEs) % of ASEs 
passing 
Filters 1 and 












970005 GAII 6 12  15168 18902 13306 189 NA NA 980028 GAII 11 8  21599 6272 5821 157 NA NA 980097 Hiseq 67 81  39582 40463 36080 223 110 0.30 980417 Hiseq 60 90  45120 42985 40740 445 119 0.29 980437 Hiseq 72 90  42355 40033 37190 377 118 0.32 990172 Hiseq 46 70  42315 31646 30692 248 68 0.22 990475 Hiseq 49 87  42349 32888 31926 289 57 0.18 2000256 GAII 15 7  22583 14223 12452 248 NA NA 2000521 GAII 17 8  25607 18715 17405 152 NA NA 2000639 Hiseq 84 63  38376 37745 34329 249 96 0.28 2000721 Hiseq 86 81  40264 41112 36209 812 300 0.83 2000892 Hiseq 56 93  39870 43230 37234 533 261 0.70 2000986 Hiseq 83 77  39627 40874 35371 825 311 0.88 20020032 GAII 6 25  14103 16839 11223 295 NA NA 43658255 Hiseq 84 78  36203 39941 33247 146 68 0.20 57689477 Hiseq 66 69  42743 41192 36243 1103 408 1.13 57689477_rep Hiseq 57 92  42879 41420 36476 1170 394 1.08 Unique ASEs in all samples 53,277 51,855 47,167 3450 545 1.11 
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To obtain an overview of the differences in alternative splicing across individual tumors, 
I used Daisy (included in R package cluster version 1.14.4) to cluster 17 tumor samples 
and 17 normal samples based on their Ѱ matrices. As shown in Figure 13, there are two 
major clusters representing low coverage and high coverage samples. Note that all tumor 
samples with low coverage were clustered together and away from high coverage tumor 
samples, but clustered together with low normal samples. Taking this into account, only 
12 tumor-normal pairs with high coverage were used for subsequent analyses. 
Hierarchical clustering of the high coverage samples based on splicing pattern of ASEs 
clearly separated tumor samples from normal samples with two exceptions that had low 
tumor content (Figure 14). There were three major clusters including two that represented 
normal samples, and one cluster that contained both tumor and normal samples. This mix 
cluster included two subgroups that corresponded to normal and tumor samples (Figure 
14). One gastric cancer specific spliceform CD44 v8-10 seems concordant with 
hierarchical clustering of Hi-seq samples based on MISO-derived relative abundance of 
ASEs. CD44 v8-10 was expressed at extremely low levels in one major normal cluster 





Figure 13 Clustering of 17 tumor-normal pairs using all ASEs with FPKM > 0.5. 




Figure 14 Clustering of 12 high coverage tumor-normal pairs using all ASEs with 
FPKM > 0.5. 





Figure 15 Ѱ values of spliceform CD44v8-10 in 12 high-coverage tumor-normal 
pairs. 
Samples were sorted according to clustering in Figure 14. 
2.2.4. Functional enrichment analysis of AS in gastric cancer  
I investigated the biological themes associated with the 320 genes containing the 545 
ASEs that passed Filters 1 and 2 (Sup Table 5) and that were consequently likely to 
involve private tumor-associated spliceforms. To do this, I used DAVID (Huang da et al., 
2009) to carry out an enrichment analysis of these 320 genes against the Gene Ontology 
(GO) functional categories (Carbon et al., 2009) and against the Kyoto Encyclopedia of 
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Genes and Genomes (KEGG) pathway database (Kanehisa et al., 2012). I used the 
background gene set with at least one ASE expressed higher than 0.5 FPKM.  
The GO categories enriched in these 320 genes are shown in Sup Tables 6, 7, and 8. The 
GO categories for which these genes were significantly enriched include GO Molecular 
Functions "cytoskeleton protein binding", "actin binding", "microtubule binding" and 
"structural constituent of cytoskeleton"—GO categories related to cell motility. In 
addition, these genes were also enriched for GO categories involved in phosphorylation 
and for the GO Biological Process categories "mRNA processing" and "RNA splicing". 
Analysis of the 320 genes with ASEs that passed Filters 1 and 2 against the KEGG 
database (Kanehisa et al., 2012) showed significant enrichment in four pathways (Table 
10), including three involved in cell-cell interaction: “adherens junction”, “tight junction”, 
and “focal adhesion”. 
By contrast, I investigated the biological themes associated with the 1,932 genes at 
similar expression level with 320 genes that were likely to involve tumor-associated 
spliceforms.  Analysis of these 1,932 control genes shows significant enrichment in the 
ribosomal and Galactose metabolism pathways. The GO categories for which these genes 
were significantly enriched in included GO-annotated molecular functions such as 
"structural constituent of ribosome", "protein transporter activity”. In addition, these 
genes were also enriched for GO categories involved in GO Biological Process categories 




Table 10 KEGG pathways enriched in candidate tumor-associated ASEs that passed 
Filter 2 
KEGG term KEGG id P-value Genes Benjamini 
Adherens 
junction 
hsa04520 2.29E-04 CSNK2A1, PTPRF, CTNND1, ACTN1, 
INSR, ACP1, TCF7L2, VCL 
0.02 
Tight junction hsa04530 1.41E-03 EPB41L2, EPB41L3, CLDN7, CSNK2A1, 




hsa04512 2.32E-03 LAMA2, CD47, CD44, TNC, COL6A3, 
ITGB4, FN1 
0.06 
Focal adhesion hsa04510 5.13E-03 LAMA2, CCND3, TNC, COL6A3, ITGB4, 
ACTN1, FLNB, FLNA, VCL, FN1 
0.10 
2.2.5. Analysis of ASEs in Lauren classification tumor type 
In order to find out if particular ASEs were associated with different Lauren classification 
tumor types; we investigated ASEs in two diffuse tumor types (exclude 980417TN) and 
seven intestinal tumors (exclude 43658255TN) using a clustering approach (Figure 14). 
There were 1,594 ASEs unique to the intestinal type, 523 ASEs unique to the diffuse type, 
and 711 ASEs that were shared by both types. The number of genes that underwent 
differential splicing in intestinal type, diffuse type and both types were 805, 226 and 455 
respectively. Furthermore, we investigated the biological themes likely to be associated 
with these differentially spliced genes. The biologically themes were consequently likely 
to involve private tumor-associated spliceforms. In order to remove the possible bias 
from expression level, we used the background gene set with at least one ASE expressing 
any FPKM value higher than 0.5. Considering the limited number of tumors in each 
Lauren subtype that we studied as well as other sources of heterogeneity (including both 
the inherent heterogeneity within each Lauren subtype and the variation in the 
proportions of malignant cells in the tumors), I concluded that analysis of differences in 
alternative splicing between the two Lauren subtypes would not be informative. 
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Pathway analysis of the 805 genes with ASEs that underwent differential splicing in 
intestinal type using the KEGG database (Kanehisa et al., 2012) showed significant 
enrichment in the Wnt signaling pathway. However, we did not find any pathway for 
which diffuse type-associated spliced genes were enriched.  Genes with ASEs that 
exhibited differential splicing in both intestinal and diffuse tumors were found enriched 
in eight pathways (Table 11) including four involved in cell-cell interaction i.e. “adherens 
junction”, “tight junction”, “focal adhesion”, and "ECM-receptor interaction" and one 
involved in cell motility i.e. "regulation of actin skeleton". 
The GO categories for intestinal type-associated spliced genes were significantly 
enriched in GO-annotated biological processes such as "mRNA processing ", "RNA 
splicing" and "cell death". The diffuse type-associated spliced genes were enriched in 
"regulation of Wnt receptor signaling pathway" and spliced genes common to both types 
were enriched in "cytoskeleton organization", "cell adhesion", and "cell projection 
organization"— GO categories related to cell motility. 
Table 11 KEGG pathways enriched in candidate ASEs in intestinal tumor type only 
KEGG 
term 






TCF7, CAMK2G, CREBBP, PPP2R5C, 
TP53, SMAD4, LEF1, FZD6, CCND3, 








Table 12 KEGG pathways enriched in candidate ASEs in both intestinal and diffuse 
tumor type 
KEGG term KEEG id P-value Genes Benjamini 
Adherens 
junction 
hsa04520 1.63E-08 ACTB, PARD3, PTPRF, BAIAP2, LMO7, 
ACTN1, CTNND1, ACP1, TCF7L2, VCL, 
MAP3K7, CSNK2A1, SORBS1, FYN, INSR, 
MLLT4 
2.01E-06 
Tight junction hsa04530 1.56E-04 ACTB, CLDN7, PARD3, MAGI3, EPB41, 
ACTN1, CASK, EPB41L2, KRAS, 





hsa04810 3.97E-03 FGFR2, ACTB, ENAH, PDGFA, DIAPH2, 
BAIAP2, ITGB4, ACTN1, VCL, PTK2, 




hsa05416 7.88E-03 ACTB, EIF4G3, FYN, DMD, MYH11, 
HLA-A, HLA-G 
2.16E-01 
Focal adhesion hsa04510 1.39E-02 ACTB, PDGFA, TNC, ITGB4, ACTN1, 











hsa04670 1.78E-02 ACTB, CLDN7, PTK2, PTK2B, CTNND1, 






hsa05412 3.72E-02 ACTB, ITGA6, DMD, ITGB4, ACTN1, 
TCF7L2 
4.41E-01 
2.2.6. Genes with possible functional changes due to alternative splicing confirmed 
by RT-PCR 
For further study, we selected a subset of the  ASEs that passed Filters 1 and 2 and that 
also satisfied at least one of the following criteria: (i) the affected gene falls into one of 
the seven most enriched KEGG pathways listed above (Table 10); (ii) the gene is likely 
to be cancer associated because it is listed in the COSMIC database (Forbes et al., 2008) ; 
(iii) the gene is a kinase (Anamika et al., 2009; Druillennec et al., 2012).  Of 320 genes, 
46 genes with the ASEs satisfied at least one of these criteria. Among the genes, seven 
were previously known be functionally affected by the ASE that we detected ("Literature 
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Support" in Figure 8b, genes listed in Sup Table 9). We attempted to design RT-PCR 
assays to confirm the existence of the eight candidate tumor-associated ASEs in these 
eight genes; and successfully designed assays for six ASEs in six different genes, and one 
assay for CD44. CD44 has a complicated repertoire of alternative splicing (da Cunha et 
al., 2010; Muller et al., 1997; Srebrow and Kornblihtt, 2006) (Sup Table 10), but we 
hoped that the RT-PCR assay could distinguish, as we hypothesized, the two most 
prominent ASEs in the cell lines. The RT-PCR was carried out in RNA from cell lines 
selected for each ASE based on the MISO analysis of alternative splicing in the cell lines 
(Sup Table 10). RT-PCR confirmed the ASEs in all genes except CD44. Although RT-
PCR indicated the existence of alternative splicing in CD44 transcripts, there were many 
RT-PCR products of varying length, thereby making it impossible to assign to every 
specific spliceform. 
2.2.7. Genes with possible functional changes due to alternative splicing may relate 
to carcinogenesis and cancer progression 
Three genes that had tumor-associated spliceforms in this study have been previously 
reported in gastric cancer: CD44, FGFR2, and MST1R. The biological consequences 
alternative splicing in these genes have already been characterized, as we describe in 
detail next. 
CD44 is a cell-surface glycoprotein that plays an essential role in cell-cell interaction, cell 
adhesion and migration. The spliceform CD44v8-10 is reported to correlate with poor 
survival rate and has been suggested as a biomarker for gastric cancer stem cells (Lau et 
al., 2014; Shibuya et al., 1998). The tumor initiating capability of this spliceform has 
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been demonstrated by limiting dilution assays (Lau et al., 2014). CD44v8-10 includes 
variable usage of exons 8 to10 and was found present at higher relative abundance in 
seven tumors compared to matched normal tissue (Figure 15, 16). 
 
Figure 16 Read depth of the ASE in CD44. 
a) Read depth and reads spanning exon-exon junctions of ASE consisting of three 
skipped exons and flanking exons in 2000892T and 2000892N; b) Poster distribution of 
ψ estimated by MISO; c) annotation of ASE. 
FGFR2 (fibroblast growth factor receptor 2) is a tyrosine protein kinase. FGFR2 acts as a 
cell-surface receptor for fibroblast growth factors. It plays essential regulation roles in 
cell proliferation, differentiation, migration and apoptosis. Recently, a study has reported 
that the expression of FGFR2-IIIb/IIIc is cell type specific. FGFR2-IIIb is expressed 
mainly in epithelial cells whereas FGFR2-IIIc is expressed in stromal fibroblasts (Guo et 
al., 2012). In vitro studies revealed that FGFR2-IIIb and FGFR2-IIIc variants inhibited 
proliferation and invasion in epithelial cell lines WRO and TPC-1. However, these same 
variants were found to promote proliferation and invasion in NIH-3T3 cell line (Guo et 
60 
 
al., 2012) . The tumor volume and tumor mass of WRO cells in NSG mouse xenografts 
model with FGFR2-IIIb variant were reduced at a lower level compared to xenografts 
harboring the FGFR2-IIIc variant. FGFR2-IIIb variant promoted NIH-3T3 tumor growth 
in xenografts model more efficiently than FGFR2-IIIc variant did (Guo et al., 2012). We 
observed a higher relative expression of FGFR2-IIIb in six tumors compared to matched 
normal tissue (Figure 17).
 
Figure 17 Read depth of ASE in FGFR2. 
a) Read depth and reads spanning exon-exon junctions of ASE consisting of exons IIIb 
and IIIc and flanking exons in 2000721T and 2000721N; b) Poster distribution of ψ 
estimated by MISO; c) annotation of ASE. 
MST1R (Macrophage Stimulating 1 Receptor (C-Met-Related Tyrosine Kinase)) is a 
tyrosine kinase receptor. It acts as a cell surface receptor for macrophage-stimulating 
protein and plays various roles in regulation of cell dissociation, motility and invasion 
(Collesi et al., 1996). A spliceform of MST1R that lacks exon 11 has been identified in 
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gastric cancer. The encoded protein cannot be cleaved as a result of a truncation of 49 
amino acids in the β-chain region, rendering it constitutively activated. As a consequence, 
the over-expression of this spliceform was observed to increase cell motility and invasion 
in vitro (Collesi et al., 1996; Srebrow and Kornblihtt, 2006). We observed a higher 
relative abundance of the isoform that skipped exon 11 in two tumors than matched 
normal tissues (Figure 18).  
 
Figure 18 ASEs in MST1R.  
a) Read depth and reads spanning exon-exon junctions of ASE consisting of exon 11 and 
flanking exons in 990475T and 990475N; b) Poster distribution of ψ of isoform A 
estimated by MISO; c) annotation of ASE. 
In addition to spliceforms that has already been reported in gastric cancer, we also 
detected genes that are known to be functionally affected by the ASE. These genes have 
been studied in the context other than gastric cancer and include: CTNND1, EPB41L2, 
PTPRF and TNC. 
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CTNND1 (Catenin delta-1) has two alternative splicing events in my data: one lacks 
exons 2 and 3 and the other includes exon 18 (Keirsebilck et al., 1998). The two 
spliceforms that differ with respect to inclusion of exons 2 and 3 show differences in their 
localization within the cell. The product of the spliceform that lacks exons 2 and 3 
(isoform 3) is present at the intercellular junctions of stratified squamous epithelia. The 
product of the spliceform that contains exon 2 and 3 (isoform 1) is present in internal 
epithelia (Montonen et al., 2001). Both isoforms 1A and 3A contain exon18 but differ 
with respect to inclusion of exons 2 and 3. Isoform 1A, that includes exons 2 and 3, 
increases E-cadherin and decreases Rac1 activity. On the other hand, isoform 3A that 
lacks exons 2 and 3 decreases Cdc42 activity and increases RhoA activity. Greater 
inhibition of invasion was observed in lung cancer cells harboring isoform 1A as 
compared to cells that harbored isoform 3A. However, greater inhibition of the cell cycle 
was seen in cells with isoform 3A as compared to those with isofom 1A (Liu et al., 2009). 
We observed a switch from inclusion of exon 2 and 3 to skipping of exon 2 and 3 in five 
tumors compared to matched normal (Figure 19). In addition, we also observed a higher 
relative expression level of exon 20 in the same tumor, but its functional consequences 




Figure 19 two ASEs in CTNND1 in 2000721T and 2000721N. 
a) Read depths and reads spanning exon-exon junctions for the ASE consisting of exons 2 
and 3 and flanking exons. b) Read depths and reads spanning exon-exon junctions for the 
ASEs consisting of exon 20 and flanking exons. 
EPB41L2 (erythrocyte membrane protein band 4.1-like2) is a key element in the 
formation of the junction complexes. These complexes are important in laterally cross 
linking spectrin heterodimers along the plane of the cytoskeleton. The spliceform that 
lacks exons 16 and 17 leads to loss of the actin and spectrin binding motifs as well as 
phosphoserine and phosphotyrosine sites. Hence, the resulting encoded protein cannot 
link transmembrane proteins to the cytoskeleton (Wang et al., 2010). I also observed an 
absence of exons 16 and 17 in five tumors that were present in their matched normal 




Figure 20 ASEs in EPB41L2. 
a) Read depths and reads spanning exon-exon junctions in ASE between 2000986T and 
2000986N; b) Exons involved in the ASE. 
PTPRF (protein tyrosine phosphataes, receptor type, F) is a protein tyrosine phosphataes 
that regulates cell growth, the mitotic cycle, and differentiation. Tumor-associated 
spliceforms lack exon 11, which contains a serine residue at a site likely to be targeted for 
regulation by phosphorylation (Honkaniemi et al., 1998). We observed an absence of 
exon 11 in five tumors compared to matched normal tissue (Figure 21) 
65 
 
Figure 21 ASEs in PTPRF. 
a) Read depth and reads spanning exon-exons junctions of ASE consisting of exon 11 and 
flanking exons in 2000721T and 2000721N; b) annotation of ASE. 
TNC (Tenascin C) is an extracellular matrix protein that plays a role in cell adhesion, 
migration and metastasis (Vollmer, 1997).  Tumor-associated spliceforms generally 
contain six variable exons 10 to 14 and 16 while spliceforms that are expressed in normal 
tissue lack all variable exons (Figure 22). These variable exons encode six fibronectin 
type III (FNIII) repeats A1-A4, B and D. Tumor-associated spliceform is first cloned 
from human melanoma cell line SK-MEL-28(Siri et al., 1991) but its function in 
melanoma still remains unclear. However, in a recent study carried out in a human breast 
cell line, over-expression of spliceforms that contained exon 14 (FNIII B), exon 14 and 
16 (FNIIIB and FNIIID) or exons 10 to16 (FNIIIIA1-A4, B, C, and D) promoted cell 
proliferation and cell invasion (Hancox et al., 2009). We also observed a higher 
66 
 
expression of these tumor-associated spliceforms in six tumors than matched normal 
tissues. Therefore, we speculate that the tumor-associated spliceforms are likely to 
contribute to cancer progression. 
 
Figure 22 ASEs in TNC.  
a) Read depth and reads spanning exon-exon junction of ASE consisting of exons 10-14 
and exon 16 and flanking exons in 980437T and 980437N; b) annotation of ASE. 
Four pathways associated with tumor-associated spliceforms that we have identified 
include: Apoptosis, MAPK signaling pathway, p53 signaling pathway, and Wnt signaling 





Table 13 Candidates involved in same pathways as reported 
Pathway Genes Source 
Wnt signaling 
pathway 
CAMK2G, CCND3, TCF7L2, RUVBL1, TP53, PPP2R5C, 
CSNK2A1 candidates 
Wnt signaling 
pathway CTNNB1, PRKACB, WNT2B known 
p53 signaling 
pathway CHEK2, TSC2, EI24, TP53, CCND3, SHISA5 candidates 
p53 signaling 
pathway CD82, CDKN2A, FAS known 
MAPK signaling 
pathway MAP4K4, NF1, FGFR2, TP53, ARRB1, FLNA, FLNB, MKNK1 candidates 
MAPK signaling 
pathway PRKACB, FGFR2, FAS known 
Apoptosis TP53, PRKAR1A, IRAK1, IRAK4 candidates 
Apoptosis PRKACB, FAS known 
 
We also identified genes that were reported in other cancers or were correlated with 
cellular morphology changes. They include: ACTN1, VCL, EPB41, ITGB4, CLK4 and 
INSR. Reported observations of these tumor-associated spliceforms identified in this 




Table 14 Aberrant alternative splicing in the present data that has been reported in 
other diseases 




ACTN1 Incl Ex 19a, 
Excl Ex 19b 
Colon cancer and prostate cancer (Gardina et al., 
2006; Thorsen et al., 
2008) 
VCL Excl Ex 19 Colon cancer, bladder cancer and 
metastatic prostate cancer  
(Thorsen et al., 
2008) 
EPB41 Incl Ex 17b Nondividing suspension cultures 




ITGB4 Excl Ex 35 Colon cancer (Gardina et al., 
2006) 
CLK4 Incl Ex 4 Undifferentiated cell (Garcia-Sacristan et 
al., 2005) 
INSR Excl Ex 11 Muscle disorder (Santoro et al., 2013) 
2.2.8. Tumor specific spliceforms identified in gastric cancer 
ASEs that are specific or almost specific to tumors are of special interest, as these are 
most likely to drive oncogenesis and might serve as targets for therapeutic inhibition by 
antibodies or small molecules. Therefore, we designed Filter 3 to select the most tumor-
specific ASEs (Figure 9). 76 ASEs in 47 genes passed Filter 3 (Figure 8, Sup Table 11). 
For 8 of these ASEs, we attempted RT-PCR validation in an independent set of 14 tumors 
and matched non-malignant gastric mucosa (Sup Table 2). I restricted investigation to 
these 8 ASEs because of limited availability of cDNA from primary patient samples. We 
designed RT-PCR primer pairs for 8, of which 8 generated products of the expected size 
(Sup Table 11). However, only two of the 8 ASEs assayed by these primer pairs turned 
out to be highly tumor specific in the panel of 14 new tumor-and-normal pairs (Sup Table 
2). For the remaining ASEs, we found substantial evidence that the candidate tumor 




Figure 23 RNA-seq quantification of three predominantly tumor-specific ASEs 
a,b) COL6A3. c,d) FLNA. Panels b, d, and f show read coverage and “split reads” for a 
matched normal and tumor pair in a genomic context. The blue boxes and lines at the 
tops of the panels show the exon structure near the ASE. The main parts of the panels 
show the read depth and split reads for the normal and tumor pair. As expected, read 
depth is usually much higher in exons. “Split reads” are those that map across an exon-
exon junction and therefore provide evidence for the existence of the junction. Red 
arrows indicate the locations of alternatively spliced exons. Panels a, c, and e show the 
Ѱs of tumor-associated ASEs (y axes) in tumor (red) and matched normal samples (blue). 
Lines connect the ASEs of paired tumor and normal samples. If an ASE was not detected 
in one of the tumor or normal samples, there is no corresponding dot. For example, in 






Figure 24 Biological generality of three predominantly tumor-specific ASEs as 
determined by RT-PCR in 14 independent tumor-normal pairs.  
a) COL6A3’s 652 bp product is tumor-specific. Amplification of the short spliceform by 
the primer pair generates a 52 bp product that is not observable against a background of 
similarly sized primer-dimer products. (We were constrained to design primers with a 
very short product for the exon-skipped spliceform in order to keep the product of the 
exon-included spliceform reasonably small.) b) The larger FLNA product is 
predominantly tumor specific, i.e. faintly seen in a few normal samples. 
The three ASEs that were predominantly tumor-specific across the original 12 and 
additional 14 tumor-and-normal pairs (Figures 23 and 24) were in the following genes: 
collagen, type VI, alpha 3 (COL6A3) and filamin A, alpha, (FLNA). 
COL6A3 encodes a protein involved in cell anchoring and remodeling of the extracellular 
mix (Zanussi et al., 1992). In the data reported here, the long spliceform was 
predominantly cancer specific. This variant has been associated with bladder, prostate, 
and colon cancers (Thorsen et al., 2008), but, to my knowledge, not with gastric cancer. 
FLNA is an actin-binding protein involved in remodeling the cytoskeleton that affects cell 
shape and migration (Nakamura et al., 2011). The predominantly cancer specific ASE in 
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FLNA includes exon 45. Little is known about this variant in cancer except that it is 
present in HeLa cells (Maestrini et al., 1993). Although this spliceform of FLNA has not 
been reported to be oncogenic, the FLNA gene itself plays key roles in invasion and cell 
migration in breast (Xu et al., 2010; Zhong et al., 2010) and pancreatic cancer (Sy et al., 
2010).  
2.3. Discussion 
This analysis of RNA-seq data from 12 gastric tumors and matched normal tissues and 
from 10 gastric cancer cell lines confirms that there is abundant alternative splicing in 
these tissues and cells lines. The search for ASEs that are associated with gastric tumors 
but not normal gastric mucosa indicated that tumor-associated and tumor-specific 
alternative splicing likely makes up a small proportion of the ASEs present. 
To my knowledge, there have been few studies using RNA-seq to categorize alternative 
splicing in cancer or to look for cancer-associated spliceforms. One study (Eswaran et al., 
2013) focused on discovery of novel ASEs in three subtypes of breast cancer and 
searched for variation in spliceform abundance among breast cancer subtypes. The 
differences in focus combined with differences in analytical methodology make it 
difficult to compare the present results with those in this previous study. Another study 
examined splicing changes in the epithelial-mesenchymal transition (Shapiro et al., 2011), 
which we discuss further below. 
The results of the present study indicate that RNA-seq is a valuable tool for 
understanding alternative splicing in cancer. In particular, the rate of technical validation 
of the existence of ASEs by RT-PCR was high. We were able to confirm the existence of 
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all 8 ASEs that passed Filter 3 and for which we were able to design an RT-PCR assay 
(Figure 8). Excluding the elaborate alterative splicing of CD44, we confirmed the 
existence of 6 ASEs that passed Filter 2 and for which there was additional evidence that 
alternative splicing had functional consequences, (Figure 8). These findings suggest that 
RNA seq data as analyzed with TopHat and MISO and subject to our filtering criteria has 
reasonable specificity for detecting ASEs. 
Although technical specificity was good, in that we were able to independently confirm 
the existence of many ASEs, findings reported here suggest that strictly cancer-specific 
ASEs are rare for gastric cancer. The initial RNA-seq data suggested this (Sup Table 11), 
and only two of the candidate tumor-specific ASEs that were detected by Filter 3 and that 
we tested in the panel of 14 additional tumor-normal pairs were predominantly tumor-
specific. The corresponding genes were COL6A3 and FLNA. Based on two lines of 
supporting evidence, we propose to investigate the possible splicing-related functional 
changes of COL6A3 in gastric epithelial cancer cell lines using an in vitro assay such as 
an adhesion assay, invasion assay or cell motility assay. The two lines of evidence that 
support this hypothesis are: (1) COL6A3 is involved in cell anchoring and remodeling of 
the extracellular mix (Zanussi et al., 1992); (2) and the tumor-associated spliceform 
detected in our data has also been reported in bladder, prostate and colon cancers 
(Thorsen et al., 2008), Since FLNA has been reported to be involved in remodeling the 
cytoskeleton that affects cell shape and migration (Nakamura et al., 2011), we also 
suggest studying the invasion and migration of the tumor-associated spliceform of FLNA 
using a cell migration assay. 
In summary, our analysis identified spliceforms known to be invoved in gastric cancer. 
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These include spliceforms of FGFR2, CD44, and MST1R. We also detected the 
previously reported gastric-cancer-associated spliceforms of RAC1 and BIRC5. However, 
there was insufficient evidence for enrichment in tumors, as the previously reported 
cancer-associated spliceforms of these genes did not pass Filter 1. In addition to 
confirming known gastric cancer spliceforms, we also identified tumor-associated 
spliceforms of CTNND1, EPB41L2, PTPRF and TNC. These splice variants were 
previously known to be functionally affected in other cancers. I presented the previous 
investigations in the context of other types of cancer in Section 2.2.7. This may offer 
guidance for future functional studies of these possibly tumor-associated spliceforms. 
Furthermore, I identified tumor-associated spliceforms of ACTN1, VCL, EPB41, ITGB4, 
CLK4 and INSR that have been reported in other types of cancer or have been associated 
changes in cell morphology. Although functional changes due to altered splicing in these 
genes remains unknown, the existence of tumor-associated spliceforms in other cancers 
supports the likely importance of these spliceforms in gastric cancer. 
Changes in splicing in EMT have been the subject of several studies (Aparicio et al., 
2013; Bawa-Khalfe et al., 2012; Biamonti et al., 2012; Braeutigam et al., 2013; Brown et 
al., 2011; Reinke et al., 2012; Samatov et al., 2013; Shapiro et al., 2011; Warzecha and 
Carstens, 2012), including one that used RNA-seq to investigate global changes in 
spliceform abundance in EMT in breast cancer (Shapiro et al., 2011). There was 
substantial overlap between the KEGG pathways associated with EMT splicing changes 
in reference (Shapiro et al., 2011) and the KEGG pathways linked to cancer-associated 
ASEs in our data. Specifically, the pathways "adherens junction" and "focal adhesion" 
were shared (three out of four pathways in Table 10 and two out of four KEGG pathways 
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in Figure 8C in reference (Shapiro et al., 2011). This offers additional confirmatory 
evidence of the soundness of my analysis, and suggests that some of the gastric-cancer-
related spliceforms found in our study might be related to EMT.  
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3. Chapter 3 Comparison of methods for identifying alternative 
splicing 
Exon arrays and RNA-seq are the two techniques that have been commonly used for 
transcriptome-wide assessment of alternative splicing. In this chapter, I compare these 
two techniques with respect to their ability to detect differences in spliceform abundance 
between pairs of samples. For exon arrays, I use FIRMA analysis (Purdom et al., 2008), 
which I describe in this chapter. For RNA-seq, I use two different widely used software 
packages for analyzing alternative splicing: MISO (Katz et al., 2010b) and Cufflinks 
(Trapnell et al., 2010). MISO was described in detail in Chapter 2. In this chapter I 
compare exon arrays analyzed with FIRMA to MISO. 
Exon arrays and RNA-seq assess alternative splicing on the basis of different principles. 
The probe sets on exon arrays measure the abundance of individual, annotated (i.e., 
previously known) exons. RNA-seq also provides information on the abundance of exons, 
via depth of read coverage. However, in addition, RNA-seq can directly capture the 
sequence of exon-exon junctions when individual reads span these junctions, and RNA-
seq based on paired-end reads can also estimate the distance between the paired reads in 
the transcript. Thus, RNA-seq provides more information for assessment of alternative 
splicing. Finally, in the most general case, RNA-seq is not restricted to known transcripts, 
and is able to deal with the full complexity of the transcriptome. 
76 
 
Exon array technology 
The GeneChip®Human Exon 1.0 ST Array was developed to assess the abundance of 
individual exons along entire transcripts (Affymetrix, 2006). This is an oligonucleotide 
array with 5,362,207 features, each containing a population of (conceptually) identical 
oligos. Each feature is considered to be a "probe", and probes are grouped into 1.4 
million "probe sets". These probe sets interrogate  1 million "exon clusters" (collections 
of overlapping exons, also known as “probe selection regions”) that were inferred based 
on available human transcriptome annotations (Affymetrix, 2006). Exon arrays estimate 
the abundance of an exon based on the amount of transcriptome-derived cDNA that 
hybridizes to the exon's cognate probe set.  
Analyzing exon-array data with FIRMA 
FIRMA uses general linear models.  Assuming a zero-sum constraint for all parameters, 
this model includes the possibility of exon expression level difference or alternative 
splicing 
log2(PMijk(j)) = ci+ej+dij+pk(j)+Ɛijk(j) 
here 
ci represents the chip effect for sample i (expression level ), 
log2(PMijk(j)) is the log2 of the signal of "perfect match" (PM) probe k for sample i after 
background-correction and normalization  
ej is the relative change of exon j expression compared to the whole gene expression,  
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dij is the interaction between sample i and exon j and indicates the discrepancy of ej for 
sample i from expected exon j expression, 
pk(j) is the nested relative probe affinity effect for the k-th probe in exon j. 
Let 𝑟𝑖𝑗𝑘 = 𝑦𝑖𝑗𝑘 −  𝑐𝚤� − 𝑝𝑘�, be the residual from fitting the model. 𝑐𝚤�  is an estimate of the 
chip effect calculated from the control probe sets on the ship. 𝑝𝑘� is an estimate of the 
probe effect estimated by stand Robust Multichip Average (RMA) model. The FIRMA 
score, Fij,  for probe set j on chip i is defined as median rijk/sij, where sij is the median 
absolute deviation (MAD) of the residuals over all k. Fij measures differential alternative 
splicing. 
The FIRMA score can be calculated by the aroma.affymetrix (Purdom et al., 2008) as 
follows: (1) carry out background adjustment and quantile normalization of probes by 
Robust Multichip Average (Irizarry et al., 2003); (2) summarize the abundance of the 
entire transcript and fit probe-level models by using iteratively reweighted least squares 
(Marazzi, 1993); (3) calculate residuals and FIRMA scores. 
3.1. Materials and Methods 
3.1.1. Cell lines studied 
I used gastric cancer cell lines MKN28, NCI-N87. See Sup Table 3 (Subsection 2.1.1) for 
the characteristics of these cell lines. 
3.1.2. Laboratory methods for exon arrays 
Total RNA was extracted from frozen tissues or cell pellets using the Qiagen RNeasy 
mini kit. Samples for exon array hybridization were processed with the  Whole Transcript 
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(WT) Sense Target Labeling Assay(Affymetrix, 2006). Samples were hybridized to 
GeneChip® Human Exon 1.0 ST Arrays according to the manufacturer’s protocol and 
scanned on a GeneChip® Scanner 3000 7G 
3.1.3. Pipeline for exon array analysis 
I constructed a pipeline for exon array data to identify genes that show different 
alternative splicing between the two cell lines. The general steps of the pipeline are 
shown in Figure 25. Table 15 shows the filters applied in the second step of the pipeline. 
I term probe sets that pass these filters “good” probe sets. 
 
Figure 25 Steps in exon array analysis.  
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Table 15 Filters for excluding exon-array probe sets likely to lead to artifacts 
Pre-filter Rationale Probe sets (or genes) 
passed filter 
Core probe sets Strong annotation evidence 284,258 probe sets 
Remove probe sets that are 
both exonic and multi-target 
Probe set likely to be 
subject to cross 
hybridization (Figure 26a) 
114,389 probe sets (~40%) 
Include only probe sets for 
which the DABG (“detect 
above background”) p value 
is < 0.01 
Probe set level too low to 
be detected (Figure 26b, 
probe set for red exon) 
83,533 probe sets (~29%) 
Remove probe sets with low 
variance and high 
normalized intensity (NI < 
5) 
Probe set likely to be 
subject to cross 
hybridization (Figure 26a, 
probe sets for red exons)) 
33,665 probe sets (~12%); 
9,877 genes 
Remove genes with > 50% 
of probe sets absent 
Non-expressed gene in one 




𝑠𝑝𝑙𝑖𝑐𝑖𝑛𝑔 𝑟𝑎𝑡𝑒 =  𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 = 𝑒𝑥𝑜𝑛 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑙𝑒𝑣𝑒𝑙
𝑔𝑒𝑛𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑙𝑒𝑣𝑒𝑙 
     
Figure 26 Scenarios that may lead to artifactual predictions of alternative splicing 
events. 
Reproduced with permission from (Affymetrix, 2006).  
The FIRMA software calculates the relative change in expression level of every exon 
represented by the probe sets in the sample (Figure 27). This relative change in exon 
expression is reflected by the FIRMA score (Purdom et al., 2008) . Subsequently, I 
ranked the genes in order to generate a final list of candidates. By ranking the AS events 
on the basis of the difference in log transformed FIRMA score between paired cell lines, I 
c b a 
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set a cutoff from the distribution of log transformed score differences (Figure 27).
 
Figure 27 Raw intensities, residuals and FIRMA scores of an example gene.  
The grey lines represent control cell lines while the red lines represent cell lines with AS. 
The probe set highlighted in green is the probe set with the highest absolute FIRMA 
score. Top: raw intensity, which reflects the probe hybridizing signal; Middle: Residuals 
indicate differential alternative splicing; Bottom: FIRMA score represents relative change 





3.1.4. Laboratory methods for RNA-seq 
These were carried out as described in Subsections 2.1.2, (RNA extraction, library 
preparation, and RNA sequencing) and 2.1.3. (Read mapping). 
3.1.5. Analysis of differential splicing in RNA-seq data using MISO. 
In order to detect possible differential splicing events between cell lines, I first estimated 
the relative abundance of alternative spliceforms using MISO as described in Section 
2.1.4. I then compared the relative isoform abundance differences by calculating the 
difference between the ψ ("percent spliced isoform" or "percent spliced in") values of two 
samples. 
3.2. Results 
3.2.1. Detection of alternative splicing using exon array data 
I analyzed exon array data from cell lines MKN28 and NCI-N87 using the pipeline in 
Figure 25. As shown in Figure 28, FIRMA score differences between -2 and 2 are 
normally distributed. The distribution of FIRMA score differences of all core exon probe 
sets (Figure 28a) is similar to that of FIRMA score differences for "good” probe sets 
(Figure 28b) and FIRMA score differences for "good” probe sets in “present” genes 
(Figure 28c). After mapping the “good” probe sets in "present” genes to potential ASEs, 
the distribution of FIRMA score differences was still similar, in that FIRMA score 
differences between -2 and 2 were still normally distributed. I interpreted the FIRMA 





Figure 28 Distributions of FIRMA score differences between lines MKN28 and NCI-
N87.  
(Legend on next page.)  
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Legend for Figure 28 Distributions of FIRMA score differences between lines 
MKN28 and NCI-N87. (Figure on previous page.) 
a) All core exon probe sets. b) All probe sets that pass the filters in Table 15, i.e. “good” 
probe sets. c) “Good” probe sets from “present” genes. d) Probe sets from “present” 
genes that can be mapped to potential ASEs. e) Quantile-quantile plot comparing the 
normal distribution to the distribution of FIRMA score differences for “good” probe sets. 
f) Quantile-quantile plot comparing the normal distribution to the distribution of FIRMA 
score differences for “good” probe sets that were in “present” genes and could be mapped 
to potential ASEs. 
3.2.2. Detection of alternative splicing using RNA-seq data 
I applied the MISO pipeline as described above (Section 2.1.4) to the RNA-seq data from 
cell lines MKN28 and NCI-N87. As illustrated by the cumulative distribution curve of 
BF in Figure 29a, ~90% ASEs in MKN28 and NCI-N87 have BF values less than 2. 
Considering that the BF is defined as "the ratio of the posterior probability of the 
alternative hypothesis ΔΨ ≠ 0, to that of the null hypothesis Δ Ψ=0" (Katz et al., 2010b), 
this indicates that there is negligible evidence for alternative splicing for the majority of 
potential ASEs. The fractions of ASEs with BFs ≥ 10, 20, and 50 and 100 were 4.7%, 
3.7%, 3%, and 2.6% respectively. The original MISO paper (Katz et al., 2010b) indicated 
that ΔΨ greater than 0.2 is the minimal difference that can be validated by qRT-PCR and 
that ASEs with BF > 20 were all successfully validated by RT-PCR. As shown in Figure 
29c, the majority of the ΔΨ values provide little evidence for differential splicing 
between MKN28 and NCI-N87. Only 950 (~2%) ASEs showed differential splicing with 





Figure 29 Bayes factor, ΔѰ of ASEs in MKN28 and NCI-N87. 
a) Cumulative distribution of the Bayes factors (BF) of ASEs identified in MKN28 and 
NCI-N87. b) Distribution of ΔѰ. c) Volcano plot of all the Bayes factors (BFs) and ΔѰ’s 
for potential ASEs in MKN28 vs. NCI-N87. The horizontal dashed blue line indicates the 




3.2.3. Comparing exon array and RNA-seq detection of differences in alternative 
splicing 
To assess the capability of detecting alternative splicing via combined exon array-
FIRMA pipeline versus combined RNA-seq-MISO pipeline, I compared the ASEs 
detected by MISO to the probe sets detected by FIRMA. First, I mapped the probe sets to 
exons. Second, I extracted the alternatively spliced exons from each alternative splicing 
event annotated by MISO. Third, exons mapped to the probe sets were intersected with 
alternatively spliced exons. Finally, for those probe sets and ASEs that can be mapped to 
each other, I compared the FIRMA score and ΔѰ of these candidates. Figure 30 shows 
the numbers of ASEs detected by both FIRMA and MISO as function of the cutoffs used 
for FIRMA scores and ΔѰ for several different cutoffs for the MISO BF. The color of 
each cell in the heatmaps indicates the number of candidate ASEs detected by both 
FIRMA and MISO. The number of candidates supported by both FIRMA and MISO 
decreases as the FIRMA difference cutoff or the ΔѰ cutoff increases. Such trend tends to 
be more dramatic if both FIRMA score difference and ΔѰ cutoff increase. When  the 
FIRMA score difference cutoff was raised to 2, the number of overlapping candidates 
was reduced to an extremely low level, while such decline is less dramatic when ΔѰ 
cutoff is increased to 0.4. The contour line of the number of overlap turned out to be 
linear and indicated that the number of overlap might be a linear function of FIRMA 




Figure 30 Numbers of ASEs detected by both FIRMA and MISO as a function of 
the cutoffs for FIRMA scores and ΔѰ. 
The color represent for the number of ASEs detected by both methods. a) ASEs with a 
MISO BF > 0. b) ASEs with BF > 20. c) ASEs with BF > 100. White-colored regions 
indicate 0 ASEs.  
87 
 
Table 16 Summary of comparison of probe sets and ASEs 
 Exon array RNA seq Exon array , RNA seq comparison 





Number of probe 




mapped to probe 
sets 
Total  283,929 70,309 31,819 39,326 
After probe sets pre-
filtering 
33,665 NA 3,915 6,432 
After gene non 
express filtering 
17,359 NA 2,410 3,983 
ASEs Detectable a in 
MKN28 and NCI-
N87 










615 NA 79 155 




4 6 4 6 
a ASEs with ψ values in both cell lines. 
As shown in Table 16, 3,915 out of 33,655 probe sets from probe sets that passed pre-
filters can be mapped to alternatively used exons in 39,326 out of 70,309 prebuilt ASEs. 
In the comparative analysis of MKN28 and NCI-N87, 3,378 out of 38,184 ASEs 
identified mapped to 2,115 probe sets (Figure 31a). Of 950 ASEs that passed the basic 
filters from MISO analysis, 139 ASEs can be mapped to 154 probe sets (Figure 31 b). 
While, in 512 probe sets candidates from FIRMA analysis, 79 of them can be mapped to 
155 ASEs detected by the MISO pipeline. By intersecting the top 512 candidates from 
the FIRMA pipeline with top 950 candidates from MISO pipeline, I identified 4 probe 
sets corresponding to 6 ASEs that were supported by both platforms (Table 17). TORIAIP 
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(Figure 32) is one of the highest ranked genes and the rest are AKAP13 (Figure 33), 
LMO7 (Figure 34), and ZNF266 (Figure 35) as shown below. 
Table 17 Alternative spliced candidates between MKN28 and NCI-N87 that are 
supported by FIRMA and MISO pipelines 




MISO id ΔѰ 

























I analyzed the correlation between ΔѰ and FIRMA score difference for “good” probe sets 
that could be mapped to exons specifically belonging to one isoform of the MISO 
detected ASEs. There were 2,115 such probe sets corresponding to 3,378 ASEs (Table 
16). For these, ΔѰ correlated with the FIRMA score difference at only r2 = 0.004 
(Pearson correlation coefficient, p = 1.31 e-5, Figure 31a). The correlation is better 
(Pearson r2 = 0.013) when we restrict our attention to ASEs with BF > 20 (data not 
shown). This suggests that the ASEs that lack strong evidence for differential splicing 
have little correlation between FIRMA score difference and ΔѰ.  The correlation is better 
(Pearson r2 = 0.34) when we further restrict our attention to probe set with FIRMA score 
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difference < -2 or >2 (Figure 31b). This suggests that those probe sets with FIRMA score 
difference between -2 and 2 contribute to the correlation in a negative manner. 
Considering the distribution of FIRMA score difference of whole exome as shown in 
Figure 28, I speculate that probe sets with FIRMA score difference less than 2 may suffer 
from low signal-to-noise ratio. This noise may possibly come from the variable 




Figure 31 FIRMA difference vs. ΔѰ  
a) FIRMA difference and ΔѰ for 2,115 probe sets corresponding to 3,378 ASEs. b) 






Figure 32 Exon array and RNA-seq analysis of alternative splicing in the gene 
TORIAIP.  
a) FIRMA scores. The blue lines represent NCI-N87 while the red lines represent 
MKN28. The green highlighted probe set is the exon predicted to be skipped. b) The 
difference in coverage of the ASE of gene TOR1AIP1 in MKN28 and NCI-N87 indicates 
exon skipping in MKN28. The blue rectangle shows the exon of the probe set with a 










Figure 33 Exon array and RNA-seq analysis of alternative splicing in the gene 
AKAP13.  
a) FIRMA scores. The blue lines represent NCI-N87 while the red lines represent 
MKN28. The green highlighted probe set detects the exon predicted to be skipped. b) 
Difference in RNA-seq coverage of the ASE in MKN28 and NCI-N87 reflects the 









Figure 34 Exon array and RNA-seq analysis of alternative splicing in the gene 
LMO7. 
a) FIRMA scores. Blue lines represent cell line NCI-N87. Red lines represent MKN28. 
The green highlighted probe set detects the exon predicted to be skipped. b) The 






Figure 35 Exon array and RNA-seq analysis of alternative splicing in the gene 
ZNF266. 
a) Exon array FIRMA scores. Blue lines represent cell line NCI-N87. Red lines represent 
MKN28. The green highlighted probe set detects the exon predicted to be skipped. b) The 
difference in RNA-seq coverage between the two cell lines reflects the skipped exon. 
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3.2.4. RT-PCR validation 
We used RT-PCR to validate two candidates supported by FIRMA plus MISO. This was 
carried out as described in Subsection 2.1.6. I was able to design working primers for 2 
candidates predicated by FIRMA and confirmed all of them.   
3.3. Discussion 
The analysis of the 2 gastric cancer cell lines using exon array data with FIRMA and 
using RNA-seq data and MISO pipelines allows assessment of the performances of the 
two approaches.  
From the comparison between probe sets and ASEs, I noticed that ~55% (39,326 out of 
70,309) of prebuilt ASEs can be mapped to probe sets designed on exon array. However, 
this proportion decreased to ~10% (6,432 out of 70,309) after probe sets pre-filtering step. 
This suggests that ~90% probe sets that were designed to hybridize to possible alternative 
exons likely led to artifacts. For MISO output, ~8.8% (3,378 out of 38,184) of detectable 
ASEs can be mapped to "good probe sets" and ~16% (154 out of 950) of ASEs with BF > 
20 and |ΔѰ| > 0.2 can be mapped to "good probe sets". 
I also observed the lack of correlation of FIRMA with ΔѰ in Figure 31a (r2=0.004) for 
3,378 ASEs corresponding to 2,115 "good probe sets". However, I observed that the 
correlation between FIRMA and ΔѰ increased from r2=0.004 to r2= (Figure 31 b) when 
we focus to ASEs with BF > 20 and probe sets with FIRMA score difference < -2 or >2. 
This suggests that the 1) ASEs that lack strong evidence for differential splicing in MISO 
have display little correlation between FIRMA score differences and ΔѰ; 2) those probe 
sets with FIRMA score difference between -2 and 2 contribute to the correlation in a 
96 
 
negative manner. In corporating with and the distribution of FIRMA score difference of 
the whole exome as shown in Figure 28, I speculate that probe sets with FIRMA score 
difference less than 2 may suffer from low signal-to-noise ratio and thus have little 
correlation with ΔѰ. This noise may possibly come from the variable efficiency of 
mRNA hybridization.  
In order to further investigate the lack of correlation between FIRMA score difference 
and ΔѰ, we examined individual cases. According to the visualization of FIRMA score 
and read depth for each candidate that FIRMA and MISO cannot agree on, I found out 
that this could be explained by the false negative rates of the methods.  
For MISO, the majority of false negative cases may fall in at least one situation as below: 
(1) probe set mapped to part of the exon that underwent splicing at the 5’ end. As shown 
in Figure 36, the probe set mapped to exonic part and showed a change in expression but 
the low number of reads did not fully support the skipping of the whole exon (Figure 36); 
(2) The pre-built ASE annotation may not be consistent with the real splicing pattern. As 
shown in Figure 37 and 38, according to the pre-build ASE annotation, exons shaded in 
red were predicted to be skipped. Similarly, the probe set that pointed to an exon showed 
a change in expression measured by read depth. However, this ASE contained at least one 
exon that was unaltered (the first exon in the red rectangle, from left to right) and all 
upstream exons of this unaltered exon in NCI-N87 showed lower coverage than in 
MKN28. 
For FIRMA the majority of false negative cases may fall in at least one situation as below: 
(1) MISO predicted ASE candidates were mixed with other ASEs. Thus the exon 
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expression level may not only reflect the percentage of an isoform of one single ASE but 
a combination of a set of ASEs; (2) flanking exon expression is low and thus unable to 
provide enough reads to support either isoform of ASE; (3) FIRMA scores in duplicates 
show large difference; (4) Probe set was not hybridized properly (Figure 39, 40). The 
probe set has a large FIRMA score difference which was not reflected in the two nearby 
probe sets that mapped to the same exon. Thus, this probe set may have some hybridizing 
issue.  
From this analysis indicates that FIRMA is good at detecting at the single exon level or 
even part-exon level change. However, it seems to lack the information of two or more 
connected flanking exons MISO can consider the connection between neighboring exons. 
But when flanking exons of the ASEs (as described in Chapter 2 Section 2.1.4) were 
expressed at low level, there might not be enough reads that can support the connection 
with flanking exon. This usually happens when the real splicing cases differ from pre-
built ASE annotation. In that case, MISO fails to estimate relative abundance of 
spliceform that contain the skipped exon. Considering that the contour line (Figure 30c) 
of the number of overlap turned out to be a linear one and indicated that the number of 
overlap might be a linear function of FIRMA score difference + ΔѰ.  Here, I hypothesize 
that to increase the number of correctly detected ASEs one could select as likely true 
ASE those for which ΔFIRMA and ΔѰ satisfy the inequality ΔFIRMA + 5*ΔѰ > C, 






Figure 36 Exon array and RNA-seq analysis for the gene RNASEK-C17ORF49. 
a) FIRMA score. Blue lines represent cell line NCI-N87; red lines represent cell line 
MKN28. The green highlighted probe set is the exon predicted to be skipped. b) The 
difference in RNA-seq coverage between MKN28 and NCI-N87 does not reflect the 
skipped exon. 
Probe set region 
 










Figure 37 Exon array and RNA-seq analysis for the gene COBLL1. 
a) FIRMA scores. Blue lines represent NCI-N87. Red lines represent MKN28. The green 
highlighted probe set shows a large FIRMA difference. b) The difference in RNA-seq 
between MKN28 and NCI-N87 reflects the skipped exon. The red arrow points to the 
exon mapped to the probe set with a large FIRMA score difference.
Probe set region 
 







Figure 38 RNA-seq analysis for the entirety of the gene COLBLL1. 
Coverage of COBLL1in MKN28 and NCI-N87 across the entire gene. The red rectangle shows the region of ASEs as in Figure 37b. 
The red arrow indicates the exon and the probe set has large FIRMA score difference.






Figure 39 Exon array and RNA-seq analysis for the gene TFG. 
a) FIRMA scores. Blue lines represent cell line NCI-N87. Red lines represent cell line 
MKN28. The green highlighted probe set suggests exon skipping. b) The difference in 
the corresponding RNA-seq coverage provides no evidence of exon skipping. The red 
arrow indicates the exon mapped to the probe set with a large FIRMA score difference. 
The levels indicated by this probe set are inconsistent with levels indicated by 
neighboring probe sets in the same exon.
a 
b 
Probe set region 
 






Figure 40 RNA-seq read coverage and spanning reads across the entirety of the gene TFG in MKN28 and NCI-N87. 
Red rectangle indicates the region in Figure 39b. Red arrow indicates the exon and the probe set has a large FIRMA score difference. 




4. Chapter 4 Splicing aberration due to somatic mutations in cancer 
4.1. Introduction 
In this chapter I describe the alternative splicing analysis that I contributed to the paper 
(Poon et al., 2013). This paper analyzed the effects of a highly mutagenic herbal remedy 
that often mutated the CAG at canonical 3' splice sites to CTG; I showed that these 
mutations almost always resulted in aberrant splicing in upper urinary tract urothelial cell 
carcinomas (UTUCs) caused by exposure to this herbal remedy. 
The herbal remedies in question contain the plants of the genus Aristolochic that contain 
aristolochic acid (AA) (Kwak et al., 2012; Vanherweghem et al., 1993). AA is both an 
acute nephrotoxin and a group 1 human carcinogen known to be associated with upper 





Figure 41 Mutation counts in AA-UTUCs and other group 1 carcinogen associated 
cancers.  
a) Total number of single-nucleotide somatic mutations in the genomes of AA-UTUC, 
UV-associated melanoma, and tobacco-associated lung cancer. b) Superimposed 
individual tumor data points for the total numbers of nonsynonymous single-nucleotide 
mutations in AA-UTUC, UV-associated melanoma, tobacco-associated lung cancer, 
Opisthorchis viverrini (OV)–associated cholangiocarcinoma (CCA), and H. pylori–
associated gastric cancer (Reproduced with permission from (Poon et al., 2013), legend 
quoted verbatim). 
By whole-genome (one tumor-normal pair) and exome sequencing (nine tumor-normal 
pairs) of ten UTUC patients exposed to AA (Poon et al., 2013), we identified a strikingly 
high prevalence of somatic mutations (Figure 41). The whole-genome analysis revealed 




the average mutation rate in smoking-associated lung cancer (8 mutations/Mb) or in 
ultraviolet-radiation-associated melanoma (111 mutations/Mb). Exome sequencing 
analysis revealed 9,933 exonic somatic substitutions in 6,415 different genes in the nine 
AA-UTUCs, including 8,144 missense, 853 nonsense alterations, and 936 splice-site 
mutations.  
 
Figure 42 AA-UTUC mutational signature. 
Sequence contexts of A>T mutations in the whole genome and exomes. Mutation rates 
are expressed as fractions of the counts of the given triplet. (Reproduced with permission 
from (Poon et al., 2013), legend quoted verbatim) 
AA induces primarily A>T mutations, caused by adenine adducts formed by a metabolite 
of AA. Furthermore, the sequence context for these A>T mutations is usually 
(C|T)AG>(C|T)TG, that is, a C or T followed by an AG mutating to the C or T followed 
by TG (Figure 42). Because the most common trinucleotides at human 3' splice site is 
CAG (Figure 43), the consequence is that 3' splices are often disrupted by AA-induced 
mutations. Indeed, on average, 104 splice sites were mutated in each AA-UTUC exome. 
Furthermore, CTG mutations at 3' splice sites were in fact more common than expected 




aberrant splicing caused by these mutations; the remainder of this chapter describes this 
analysis and its results. 
 
Figure 43 Single nucleotide somatic mutations in 16 possible sequence contexts for A 
→ T transitions in the exomes of nine AA-UCC. 




Figure 44 Mutated CAGs in 3' splice sites. 
AA-UTUC and AA-treated cells have more mutated CAGs at 3' splice sites than expected 
by chance. The height of the black bar labeled “All CAGs” shows the percentage of all 
CAGs (both mutated and wild-type) occurring at 3′ splice sites. (Reproduced with 
permission from (Poon et al., 2013), legend quoted verbatim) 
4.2. Materials and Methods 
RNA sequencing was carried out by other contributors to (Poon et al., 2013), using 
methods described in the paper. 
4.2.1. RNA sequencing analysis 
First, Illumina-format “bcl” (base call) files were converted to fastq files using Illumina’s 
CASAVA 1.8 software 
(http://support.illumina.com/sequencing/sequencing/sequencing_software/casava.ilmn). I 
used Tophat 1.2 (http://tophat.cbcb.umd.edu/) to map the reads to the hg19 human 
reference genome with the ENSMEBL60 gene annotation for mapping to possible exon-
exon junctions. I visualized the exons surrounding the splice site mutations using the 
UCSC genome browser (http://genome.ucsc.edu/). Mapped reads were analyzed via 
RNA-SeQC (https://confluence.broadinstitute.org/display/CGATools/RNA-SeQC) for 
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quality control and exon level quantification. I used Cufflinks 1.3 
(http://cufflinks.cbcb.umd.edu/) for whole-transcript quantification of NMD pathway 
genes. 
4.2.2. Validation of alternative splicing by RT-PCR 
For MBOAT7, I designed primers using primer3 against flanking exons: 5'- 
CGCCTGAAGAATGGACGTAT-3', 5'- AGGCCATTTCCTTCCTCTG-3'  
4.3. Results 
4.3.1. Splice site mutation cause alternative splicing 
Exome sequencing revealed 69 likely 3' splice sites with CAG > CTG mutations in one 
tumor for which RNA-sequence data had been generated. I looked for altered splicing in 
this RNA sequence data (Figure 45). First, I selected only the 15 genes with whole-gene 
FPKM (Fragments per Kilobase per Million mappable reads) values > 2, reasoning that it 
would be impossible to detect altered splicing in transcripts with coverage lower than that 
(Figure 46). Evidence supporting the reasoning for this threshold is the fact that only ~6% 
of genes with FPKMs < 2 have high-confidence ASEs; by contrast, ~45% of genes with 





Figure 45 CAG → CTG mutations at 3’ splice sites are strongly associated with 
altered splicing.  
a) We looked for altered splicing in tumor transcripts at the locations of 15 CAG → CTG 
mutations at 3’ splice sites preceding internal exons. These were mutations in the 15 
genes with adequate coverage to assess splicing alteration (Whole gene FPKM by 
Cufflinks >2). b) As a control data set, we searched for altered splicing near 29 
unmutated 3’ splice sites with similar FPKMs (Sup Table 12). c) We tested for 
enrichment of altered splicing at the sites of the 15 CAG → CTG mutations. (Reproduced 




Figure 46 the distribution of FPKM values and the proportion of genes with 
detected ASEs. 
a) The proportion of genes ≥ 1 detectable ASE as a function of expression level 
(log2(FPKM+1)). b) The proportion of genes with ≥ 1 high-confidence ASE as function 
of expression level. Blue vertical dashed lines in a) and b) indicate FPKM = 2. 
For those cases with low expression (FPKM < 2), I found that reads that can be mapped 
to possible exons and flanking exons were too few to deduce alternative splicing. For the 
15 genes with whole-gene FPKM > 2, I calculated the coverage of the exon immediately 
3' of the mutation and also the coverage of the exons flanking that one. Of the 15 genes 
with whole-gene FPKM > 2, 4 had read coverage at the exon 3' of the mutation that was 
< 5 and therefore too low to assess for altered splicing. For the remaining 11, I visualized 
the read depth of the exons flanking the exon 3' of the mutation (Figures 47, 48, 49, 50). 
In one particular gene in tumor, I observed no evidence of altered splicing. In 6 genes in 
tumor, the exon 3' of the mutation was skipped in some transcripts. In 3 genes in tumor, 
the intron containing the mutation was retained in some transcripts. In one gene in tumor, 
all exons 5' of the mutation were absent from some transcripts. 
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I then investigated whether this aberrant splicing might be unrelated to the 3' splice site 
mutations. Using the approach just described, I searched for aberrant splicing in a control 
data set consisting of splice sites in 20 genes that had read coverage similar to those with 
3' splice-site mutations, but that had un-mutated splice sites (Sup Table 12). These 20 
genes were selected as having the closest expression levels to those of the genes with 
splice-site mutations. None showed evidence of altered splicing (Figure 45b). This is 
significantly less than observed at the mutated 3' splice sites (P < 3 x 10 -7, Fisher's exact 
test, two sided, Figure 45c) As shown in Figure 47a, the exon near the mutated 3’ splice 
site is skipped in the tumor compared to the normal sample. And such predicted exon 
skipping has been further validated by RT-PCR (Figure 47b).    
           
   
Figure 47 Altered RNA splicing in AA-UTUCs.  
a) A heterozygous splice site mutation resulted in skipping of MBOAT7 exon 3 in AA-
UTUC. b) Verification of MBOAT7 exon skipping by RT-PCR. Arrows schematically 
indicate primer locations. YL designed the primers but other contributors did the RT-
PCR. (Reproduced with permission from (Poon et al., 2013), legend quoted verbatim) 
 
a                                                                       




Figure 48 A heterozygous 3’ splice site mutation results in skipping of RFC2 exon 10 
in AA-UTUC.  
Bridging reads, confirming the exon skipping, are shown. (Reproduced with permission 
from (Poon et al., 2013); legend quoted verbatim.) 
 
Figure 49 A heterozygous 3' splice site mutation in the MARS gene results in 





Figure 50 A 3' splice site mutation in the AEBP1 gene in an AA-UTUC results in 
loss of all exons 5' of the mutation. 
Lost exons indicated by red rectangle. 
Considering that aberrant mRNA splicing in AA-UTUC may result in transcripts with 
premature stop codons which may trigger nonsense-mediated decay (NMD) mechanisms 
(Govindan et al., 2012; Nikolaev et al., 2012), I suspected that the NMD genes may be 
up-regulated in tumor samples. Therefore I examined the mRNA levels of 15 NMD-
pathway genes previously reported to be up-regulated in response to aberrant splicing 
(Stiborova et al., 2003). Using RNA-sequence data, I compared the expression levels of 
these genes between the AA- UTUC tumor and the matched non-malignant sample. 13 of 
these genes had higher expression in the tumor and two had lower expression. The 





Figure 51 Transcript levels of nonsense-mediated decay (NMD) in an AA-exposed 
tumor and matched non-malignant tissue. 
NMD transcripts are systematically up-regulated in the tumor compared to adjacent 
normal tissue. P-value calculated by Wilcoxon signed-rank test. (FPKMs computed by 
YL from RNA-sequencing data; figure plotted by another contributor) (Reproduced with 
permission from (Poon et al., 2013); legend quoted verbatim.) 
4.3.2. Discussion 
Analysis of alternative splicing in RNA sequencing data from an AA-UTUC tumor 
showed that CAG > CTG mutations at 3' splice sites almost always disrupted splicing in 
genes with transcript levels high enough to allow assessment. Consistent with substantial 
aberrant splicing in this tumor, NMD genes were significantly up-regulated. These 
findings, in conjunction with the observation that AA-UTUC tumors in fact contain more 
3' splice mutations than expected by chance (Figure 44) lead us to speculate the aberrant 




5. Chapter 5 Conclusion 
5.1. Global analysis of alternative splicing in gastric cancer 
RNA-seq combined with TopHat, MISO, and additional filters can effectively identify 
alternative splicing in cancer. I was able to re-discover tumor-associated spliceforms that 
have been previously reported in gastric cancer, including those in the genes CD44, 
FGFR2, and MST1R. Pathways already known to be involved in gastric carcinogenesis 
that are linked to tumor-associated spliceforms that I identified include apoptosis, MAPK 
signaling, p53 signaling, and Wnt signaling (Table 13).  
In addition, I also detected gastric-cancer-associated alternative splicing in genes that 
were previously known to be functionally affected by the ASE in cancers other than 
gastric cancer. These genes have been studied in contexts other than gastric cancer and 
include CTNND1, EPB41L2, PTPRF and TNC. Analysis of the 320 genes with ASEs that 
passed Filters 1 and 2 showed significant enrichment in four KEGG (Kanehisa et al., 
2012) pathways (Table 10). These include three involved in cell-cell interaction: 
“adherens junction”, “tight junction”, and “focal adhesion”. These overlap substantially 
with the KEGG pathways associated with EMT splicing changes in (Shapiro et al., 2011). 
I also identified gastric-cancer-associated alternative spliceforms that were not previously 
linked to this disease, and some of these spliceforms, those in COL6A3 and FLNA, were 
predominately tumor-specific in the tumor and normal samples I studied. Alternative 
splicing in cancer is relatively unexplored, and it appears to be complicated by the 
heterogeneity of cancer and by the little-studied diversity of spliceforms in normal tissues. 
Despite these challenges, the study here provides evidence that RNA-seq-based 
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approaches can reveal cancer associated spliceforms and even predominantly cancer-
specific spliceforms. 
The ability to detect ASEs appears to be highly dependent on read depth. The MISO-
calculated confidence intervals for Ѱ values tend to decrease with increasing ASE 
expression level. In addition, the number of detected ASEs is also highly correlated with 
read depth. These effects strongly influence the unsupervised clustering of tumor and 
normal samples based on MISO-derived Ѱ values, in which low-read-depth tumors 
cluster together (Figures 13, 14).  
If we restrict attention to the high-coverage sample, however, hierarchical clustering 
based on Ѱ values clearly separated tumor samples from normal samples with two 
exceptions. These two exceptions were tumors with low proportions of malignant cells. 
The hierarchical clustering of the 24 high-coverage samples seems concordant with the 
relative abundance of one gastric cancer specific spliceform CD44 (Figure 15). 
5.2. Comparison of methods for identifying alternative splicing 
RNA-seq combined with MISO and exon arrays combined with FIRMA seems to detect 
largely disjoint sets of alternative splicing events. This may be due to the selection of the 
exon-array probe sets, because ~90% of probe sets that can be mapped to alternatively 
incorporated exons in ASEs do not pass the filters described in Table 15. 
The lack of correlation between FIRMA and ΔѰ contributed by those probesets with 
FIRMA score differences between -2 and 2 and ASEs with BF < 20. This indicates that 1) 
the ASEs that lack strong evidence for differential splicing may contribute to the 
correlation of FIRMA and ΔѰ in a negative manner; 2) the probe sets suffere from the 
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noise that may possibly come from the variable hybridizing efficiency of mRNA have 
little correlation with ΔѰ. The divergence between FIRMA and MISO may also be 
explained by the false negative rates of the methods. For MISO, the majority of false 
negative cases may fall in at least one situation as below: (1) probe set mapped to part of 
the exon that underwent splicing at the 5’ end. (2) The pre-built ASE annotation may not 
be consistent with the real splicing pattern. For FIRMA the majority of false negative 
cases may fall in at least one situation as below: (1) MISO predicted ASE candidates 
were mixed with other ASEs; (2) Flanking exon expression is low and thus unable to 
provide enough reads to support either isoform of ASE; (3) FIRMA scores in duplicates 
show large differences; 4) Probe set was not hybridized properly. 
MISO plus FIRMA point out four probe sets corresponding to six ASEs and I confirmed 
two of them (Table 17). At least ΔѰ (calculated by MISO) and FIRMA score of ASEs 
are rarely diametrically opposed in their assessment of exon inclusion (e.g ΔѰ=0.8 while 
FIRMA score = -5). Most ASEs with a high FIRMA score but low | ΔѰ | appear to suffer 
from complicated diversity of spliceforms. Thus, pure FIRMA score or | ΔѰ | value may 
not provide enough information of splicing but need to be considered with all splicing 
events that share the same location case by case. Here, I hypothesize that to increase the 
number of correctly detected ASEs one could select as likely true ASE those for which 
ΔFIRMA and ΔѰ satisfy the inequality ΔFIRMA + 5*ΔѰ > C, where 5 is selected by 




5.3. Integrative analysis of alternative splicing and single nucleotide variant in 
cancer 
The RNA-seq and MISO analysis of AA-associated UTUCs in (Poon et al., 2013) 
revealed altered splicing in 10 out of 11 3’ splice sites at which there was a CAT -> CTG. 
This shows a strong connection between single-nucleotide mutations and aberrant 
splicing in AA-UTUCs. Consistent with substantial aberrant splicing in AA-UTUCs, 
NMD genes were also significantly up-regulated. Considering the many 3' splice site 
mutations in AA-UTUCs, aberrant splicing may well contribute to their pathogenesis. My 
work in (Poon et al., 2013) shows how study of somatic mutations in cancer can be 
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Sup Table 1 Genetic and epigenetic alterations in gastric cancer 
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Sup Table 2 Characteristics of primary tumors 
Sample 
















Samples in the initial set of 12 tumor-normal pairs 
2000256 RNA-Seq NA 61 F T4a N2 m0 poorly differentiated N mixed/ other 
2000521 RNA-Seq NA 67 F T4a T3b m0 poorly differentiated NA diffuse 
20020032 RNA-Seq 50% Intestinal 56 M T4a N1 m1 
moderately 
differentiated N intestinal 
970005 RNA-Seq 60% Diffuse 69 M T4b N3a m0 moderately differentiated NA intestinal 
980028 RNA-Seq 70% Intestinal  61 M T2 N0 m0 
moderately 
differentiated NA intestinal 
2000639 Hi-Seq 30% Intestinal 70 M T4a N3a m1 
moderately 
differentiated Y intestinal 
2000721 Hi-Seq 70% Intestinal  71 M T4a T3b m1 
poorly 
differentiated Y diffuse 
2000986 Hi-Seq 80% Diffuse 39 F T4a T3b m1 poorly differentiated NA diffuse 
43658255 Hi-Seq 30-40% Intestinal 67 M T4a N3a m1 
moderately 
differentiated NA intestinal 
57689477 Hi-Seq 70 - 80% Intestinal 84 F T1b N0 m0 
moderately 
differentiated N intestinal 
990172 Hi-Seq NA 60 M T3 N3a m0 poorly differentiated Y intestinal 
990475 Hi-Seq NA 71 M T2 N1 m0 well differentiated NA intestinal 
980417 Hi-Seq NA 67 M T3 N3 m0 poorly differentiated Y diffuse 
980437 Hi-Seq NA 68 F T3 N3 m0 poorly differentiated NA intestinal 




















2000892 Hi-Seq 80% intestinal 71 F T2a N1 m0 
moderately 
differentiated N intestinal 
Samples in the set of 14 tumor-normal pairs used to assess generality of gastric-cancer specificity by RT-PCR 
2000639 RT-PCR 30% Intestinal 70 M T4a N3a m1 
moderately 
differentiated Y intestinal 
990041 RT-PCR NA 40 M T4b N2 m0 poorly differentiated Y intestinal 
61669256 RT-PCR 30% Intestinal 57 M T4b N2 m0 
moderately 
differentiated Y diffuse 
980252 RT-PCR 70% Intestinal  66 M T4a N1 m1 
poorly 
differentiated NA intestinal 
980369 RT-PCR NA 47 F T2 N0 m0 poorly differentiated NA diffuse 
980417 RT-PCR NA 67 M T4a T3b m0 poorly differentiated Y diffuse 
990136 RT-PCR NA 76 M T1b N0 m0 moderately differentiated N intestinal 
990172 RT-PCR NA 60 M T3 N3a m0 poorly differentiated Y intestinal 
2000068 RT-PCR NA 64 F T1b N0 m0 moderately differentiated Y intestinal 
2000877 RT-PCR >90% Diffuse 45 M T2 N1 m0 
poorly 
differentiated NA intestinal 
980390 RT-PCR NA 78 F T1b N1 m0 moderately differentiated NA intestinal 
990489 RT-PCR NA 79 M T2 N0 m0 poorly differentiated NA mixed/ other 
2000038 RT-PCR NA 65 F T4a N3a m0 poorly differentiated Y intestinal 
2000441 RT-PCR NA 53 M T4a N3a m0 poorly differentiated N diffuse 
NA = not available; Y = yes, N = no. 
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Sup Table 3 Characteristics of cell lines 








Specimen site WHO histology Lauren classification 








NCI-N87 ATCC NA M NA Liver metastasis 
well differentiated 
adenocarcinoma intestinal 
SNU-16 ATCC 33 F Korea Ascites poorly differentiated adenocarcinoma diffuse 
KATO-III HSSRB 55 M Japan Pleural effusion 
signet ring cell 














AZ521 HSSRB NA NA NA Primary tumor NA NA 
RERF-GC-1B HSSRB 41 M Japan Lymph node metastasis adenocarcinoma NA 
YCC3 YCC 58 M NA Acsites NA NA 
YCC16 YCC 40 F NA Cancer cells from blood NA NA 
NA = not available 
ATCC=American Type Culture Collection  
HSSRB = Health Science Research Resources Bank  
YCC = Yonsei Cancer Centre, S.Korea 
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Sup Table 4 RNA-Seq reads quality and mapping summary-Part A 



















2000639N HiSeq2000 1.79E+08 8.94E+07 6.35E+07 2.87E+07 76 1.71E+08 7.6E-03 6.35E+07 63 
2000639T HiSeq2000 2.30E+08 1.15E+08 8.41E+07 2.03E+07 76 1.98E+08 6.9E-03 8.41E+07 84 
2000721N HiSeq2000 2.20E+08 1.10E+08 8.11E+07 1.94E+07 76 1.91E+08 6.2E-03 8.11E+07 81 
2000721T HiSeq2000 2.44E+08 1.22E+08 8.64E+07 2.27E+07 76 2.06E+08 7.3E-03 8.64E+07 86 
2000986N HiSeq2000 2.07E+08 1.04E+08 7.74E+07 1.75E+07 76 1.81E+08 6.0E-03 7.74E+07 77 
2000986T HiSeq2000 2.30E+08 1.15E+08 8.31E+07 2.06E+07 76 1.96E+08 6.9E-03 8.31E+07 83 
43658255N HiSeq2000 2.16E+08 1.08E+08 7.85E+07 1.74E+07 76 1.83E+08 6.0E-03 7.84E+07 78 
43658255T HiSeq2000 2.32E+08 1.16E+08 8.44E+07 1.95E+07 76 1.98E+08 6.4E-03 8.44E+07 84 
57689477N HiSeq2000 1.54E+08 7.70E+07 6.89E+07 4.06E+06 76 1.46E+08 6.5E-03 6.89E+07 69 
57689477T HiSeq2000 1.52E+08 7.62E+07 6.62E+07 4.79E+06 76 1.42E+08 7.0E-03 6.62E+07 66 
990172N HiSeq2000 1.51E+08 7.53E+07 6.99E+07 1.38E+07 76 1.67E+08 7.6E-03 6.99E+07 70 
990172T HiSeq2000 1.08E+08 5.38E+07 4.62E+07 3.79E+06 76 9.97E+07 7.4E-03 4.62E+07 46 
990475N HiSeq2000 2.04E+08 1.02E+08 8.66E+07 3.69E+07 76 2.24E+08 1.2E-02 8.65E+07 87 
990475T HiSeq2000 1.27E+08 6.37E+07 4.90E+07 1.12E+07 76 1.12E+08 1.1E-02 4.90E+07 49 
2000892N HiSeq2000 2.35E+08 1.18E+08 9.28E+07 7.47E+06 76 2.03E+08 5.32E-03 9.27E+07 93 
2000892T HiSeq2000 1.48E+08 7.42E+07 5.57E+07 5.02E+06 76 1.23E+08 5.67E-03 5.57E+07 56 
57689477N_rep HiSeq2000 2.37E+08 1.18E+08 9.23E+07 6.89E+06 76 2.01E+08 5.09E-03 9.23E+07 92 
57689477T_rep HiSeq2000 1.55E+08 7.76E+07 5.75E+07 5.57E+06 76 1.28E+08 5.73E-03 5.75E+07 57 
980097N HiSeq2000 2.59E+08 1.29E+08 8.10E+07 1.46E+07 76 1.92E+08 8.61E-03 8.09E+07 81 
980097T HiSeq2000 1.93E+08 9.64E+07 6.69E+07 9.39E+06 76 1.54E+08 7.45E-03 6.68E+07 67 
980417N HiSeq2000 2.57E+08 1.28E+08 9.04E+07 1.10E+07 76 2.05E+08 6.99E-03 9.03E+07 90 
980417T HiSeq2000 1.68E+08 8.39E+07 6.02E+07 6.20E+06 76 1.34E+08 6.14E-03 6.01E+07 60 
980437N HiSeq2000 2.36E+08 1.18E+08 8.97E+07 1.27E+07 76 2.07E+08 7.17E-03 8.97E+07 90 
980437T HiSeq2000 1.90E+08 9.50E+07 7.22E+07 6.29E+06 76 1.59E+08 5.79E-03 7.22E+07 72 
AGS GAIIx 3.73E+07 1.86E+07 1.71E+07 1.10E+06 38 3.60E+07 7.0E-03 1.71E+07 17 
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AZ521 GAIIx 4.01E+07 2.01E+07 1.93E+07 1.42E+06 38 4.09E+07 7.1E-03 1.93E+07 19 
GCN2000256 GAIIx 1.55E+07 7.75E+06 6.76E+06 1.27E+06 38 1.52E+07 7.4E-03 6.76E+06 7 
GCN2000521 GAIIx 1.79E+07 8.96E+06 8.34E+06 6.44E+05 38 1.77E+07 6.0E-03 8.34E+06 8 
GCN20020032 GAIIx 4.35E+07 2.18E+07 2.48E+07 2.27E+06 38 5.31E+07 6.6E-03 2.48E+07 25 
GCN970005 GAIIx 2.74E+07 1.37E+07 1.19E+07 2.37E+06 38 2.70E+07 7.8E-03 1.19E+07 12 
GCN980028 GAIIx 1.42E+07 7.09E+06 8.29E+06 1.52E+06 38 1.85E+07 6.7E-03 8.29E+06 8 
GCT2000256 GAIIx 3.24E+07 1.62E+07 1.53E+07 1.68E+06 38 3.32E+07 8.0E-03 1.53E+07 15 
GCT2000521 GAIIx 3.54E+07 1.77E+07 1.66E+07 1.44E+06 38 3.56E+07 6.9E-03 1.66E+07 17 
GCT20020032 GAIIx 1.22E+07 6.09E+06 5.52E+06 6.48E+05 38 1.20E+07 7.7E-03 5.52E+06 6 
GCT970005 GAIIx 1.34E+07 6.68E+06 6.19E+06 7.37E+05 38 1.34E+07 7.2E-03 6.19E+06 6 
GCT980028 GAIIx 2.25E+07 1.12E+07 1.08E+07 7.13E+05 38 2.29E+07 7.8E-03 1.08E+07 11 
IM95 GAIIx 3.12E+07 1.56E+07 1.48E+07 1.39E+06 38 3.19E+07 8.3E-03 1.48E+07 15 
KatoIII HiSeq2000 1.96E+08 9.81E+07 7.67E+07 1.68E+07 76 1.74E+08 1.1E-02 7.67E+07 77 
MKN28 GAIIx 7.21E+07 3.61E+07 3.34E+07 2.71E+06 38 7.14E+07 7.9E-03 3.34E+07 33 
NCI-N87 GAIIx 3.39E+07 1.70E+07 1.59E+07 1.01E+06 38 3.36E+07 6.6E-03 1.59E+07 16 
RERFGC1B HiSeq2000 1.58E+08 7.90E+07 6.15E+07 1.32E+07 76 1.40E+08 1.1E-02 6.15E+07 61 
SNU16 GAIIx 2.64E+07 1.32E+07 1.20E+07 1.06E+06 38 2.58E+07 8.1E-03 1.20E+07 12 
YCC16 GAIIx 2.06E+07 1.03E+07 9.58E+06 6.31E+05 38 2.02E+07 6.6E-03 9.58E+06 10 





Sup Table 4 RNA-Seq reads quality and mapping summary-Part B 
Sample Sequencer Chimeric pairs 
Proportion 























2000639N HiSeq2000 3.60E+05 0.98 0.86 0.121 0.019 0.857 111,370 25,075 
2000639T HiSeq2000 1.01E+06 0.97 0.89 0.085 0.029 0.886 111,462 25,777 
2000721N HiSeq2000 5.94E+05 0.97 0.89 0.081 0.031 0.888 116,728 26,981 
2000721T HiSeq2000 8.28E+05 0.97 0.87 0.093 0.032 0.874 115,982 27,335 
2000986N HiSeq2000 6.56E+05 0.97 0.89 0.077 0.030 0.893 114,967 26,006 
2000986T HiSeq2000 9.33E+05 0.97 0.89 0.083 0.030 0.887 113,286 26,305 
43658255N HiSeq2000 7.19E+05 0.97 0.89 0.080 0.033 0.887 114,045 26,277 
43658255T HiSeq2000 7.81E+05 0.97 0.89 0.082 0.031 0.886 116,393 27,093 
57689477N HiSeq2000 5.30E+05 0.97 0.89 0.085 0.030 0.885 111,567 24,906 
57689477T HiSeq2000 6.67E+05 0.96 0.86 0.101 0.034 0.864 113,839 26,565 
990172N HiSeq2000 2.72E+05 0.98 0.87 0.110 0.018 0.872 109,259 24,260 
990172T HiSeq2000 5.29E+05 0.97 0.89 0.083 0.029 0.887 110,989 25,227 
990475N HiSeq2000 3.09E+05 0.99 0.89 0.103 0.011 0.885 109,734 24,379 
990475T HiSeq2000 3.49E+05 0.97 0.87 0.094 0.033 0.872 112,829 25,824 
2000892N HiSeq2000 6.20E+05 0.97 0.882 0.089 0.028 0.882 116,086 26,645 
2000892T HiSeq2000 5.67E+05 0.97 0.871 0.102 0.027 0.871 109,374 24,638 
57689477N_rep HiSeq2000 7.26E+05 0.97 0.892 0.080 0.027 0.892 112,961 25,439 
57689477T_rep HiSeq2000 5.04E+05 0.97 0.856 0.110 0.033 0.856 113,693 26,376 
980097N HiSeq2000 4.45E+05 0.94 0.808 0.128 0.062 0.808 114,023 25,904 
980097T HiSeq2000 6.67E+05 0.97 0.885 0.088 0.022 0.885 108,389 24,558 
980417N HiSeq2000 7.98E+05 0.97 0.866 0.105 0.027 0.866 116,322 27,038 
980417T HiSeq2000 4.81E+05 0.97 0.867 0.101 0.031 0.867 114,541 26,266 
980437N HiSeq2000 5.35E+05 0.98 0.888 0.090 0.018 0.888 114,386 26,015 
980437T HiSeq2000 7.90E+05 0.97 0.875 0.094 0.030 0.875 114,083 26,319 
AGS GAIIx 2.25E+05 0.97 0.89 0.075 0.034 0.890 90,917 20,574 
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Sample Sequencer Chimeric pairs 
Proportion 























AZ521 GAIIx 2.95E+05 0.96 0.88 0.078 0.038 0.884 93,539 21,640 
GCN2000256 GAIIx 9.46E+04 0.96 0.89 0.072 0.041 0.887 94,279 21,078 
GCN2000521 GAIIx 1.03E+05 0.96 0.89 0.074 0.039 0.887 101,626 22,377 
GCN20020032 GAIIx 1.91E+05 0.98 0.92 0.056 0.022 0.922 97,844 22,210 
GCN970005 GAIIx 1.75E+05 0.96 0.88 0.081 0.038 0.881 100,647 23,092 
GCN980028 GAIIx 6.24E+04 0.98 0.92 0.059 0.023 0.918 77,547 18,243 
GCT2000256 GAIIx 2.88E+05 0.96 0.88 0.083 0.037 0.880 99,490 22,815 
GCT2000521 GAIIx 1.76E+05 0.96 0.88 0.080 0.038 0.882 108,839 24,640 
GCT20020032 GAIIx 8.68E+04 0.97 0.89 0.072 0.034 0.894 94,179 21,097 
GCT970005 GAIIx 1.15E+05 0.97 0.89 0.076 0.034 0.890 92,462 20,800 
GCT980028 GAIIx 1.50E+05 0.97 0.90 0.069 0.033 0.899 95,953 21,546 
IM95 GAIIx 1.95E+05 0.95 0.86 0.089 0.050 0.861 91,684 21,118 
KatoIII HiSeq2000 1.15E+06 0.97 0.89 0.074 0.032 0.893 103,902 24,459 
MKN28 GAIIx 5.05E+05 0.96 0.89 0.077 0.037 0.886 97,887 23,122 
NCI-N87 GAIIx 2.30E+05 0.96 0.88 0.078 0.039 0.882 94,894 21,481 
RERFGC1B HiSeq2000 6.91E+05 0.96 0.87 0.093 0.037 0.870 110,438 25,719 
SNU16 GAIIx 2.17E+05 0.96 0.87 0.092 0.041 0.867 91,608 20,845 
YCC16 GAIIx 1.54E+05 0.96 0.88 0.081 0.038 0.881 91,945 20,380 





Sup Table 5 ASEs candidates that passed filters 1 and 2 
MISO id for the ASE constitutes of the location of upstream, downstream and skipped exon; Max is the largest ΔΨ between 
tumor and paired normal; TN with max ΔΨ refer to the tumor and paired sample with the largest ΔΨ. #TN means the number 
of tumor normal paired show ΔΨ by MISO (Ψs,Ti - Ψs,Ni > 0.2, BF > 100). All candidates were sorted based on the absolute 
value of max ΔΨ first and then by #TN. 





























-0.96 57689477T_rep_vs_57689477N_rep 10 
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-0.96 57689477T_rep_vs_57689477N_rep 9 
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0.92 57689477T_rep_vs_57689477N_rep 9 
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0.87 57689477T_rep_vs_57689477N_rep 7 
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-0.84 57689477T_rep_vs_57689477N_rep 6 
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0.84 2000986T_vs_2000986N 4 










-0.82 57689477T_vs_57689477N 8 
































0.8 57689477T_vs_57689477N 3 
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-0.78 57689477T_vs_57689477N 5 
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0.76 2000986T_vs_2000986N 9 
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0.74 2000986T_vs_2000986N 10 
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-0.74 2000639T_vs_2000639N 7 
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-0.73 2000986T_vs_2000986N 8 
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0.72 2000986T_vs_2000986N 10 
162 
 







































0.7 2000986T_vs_2000986N 9 










-0.7 2000721T_vs_2000721N 4 
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-0.69 2000986T_vs_2000986N 9 





































-0.67 57689477T_vs_57689477N 9 
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-0.67 57689477T_rep_vs_57689477N_rep 2 








































0.65 2000986T_vs_2000986N 2 
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0.63 57689477T_vs_57689477N 4 
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0.61 57689477T_vs_57689477N 8 
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0.6 2000892T_vs_2000892N 4 
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0.6 57689477T_rep_vs_57689477N_rep 3 
LA16c-398G5.2 chr16:685060:685340:-@chr16:685518:685774:-@chr16:686094:686366:- -0.6 980437T_vs_980437N 2 









































0.59 980097T_vs_980097N 4 
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-0.58 57689477T_vs_57689477N 5 
LA16c-398G5.2 chr16:686094:686290:-@chr16:685612:685774:-@chr16:684719:684797:- 0.58 980437T_vs_980437N 4 
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0.57 57689477T_rep_vs_57689477N_rep 2 
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0.55 980437T_vs_980437N 6 
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-0.54 980437T_vs_980437N 4 




















0.54 990475T_vs_990475N 2 
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0.53 57689477T_vs_57689477N 4 
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0.51 2000986T_vs_2000986N 7 
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-0.5 2000986T_vs_2000986N 7 
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-0.5 980097T_vs_980097N 2 
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-0.49 57689477T_vs_57689477N 3 
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0.49 57689477T_vs_57689477N 2 









































0.48 2000892T_vs_2000892N 4 
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0.46 2000892T_vs_2000892N 3 
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0.45 57689477T_rep_vs_57689477N_rep 4 
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0.44 57689477T_rep_vs_57689477N_rep 5 
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-0.43 2000639T_vs_2000639N 6 
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-0.42 980437T_vs_980437N 3 
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0.42 2000986T_vs_2000986N 2 


























0.41 57689477T_vs_57689477N 2 
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-0.4 980437T_vs_980437N 3 
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-0.39 2000721T_vs_2000721N 5 
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-0.39 2000986T_vs_2000986N 3 
































0.38 57689477T_rep_vs_57689477N_rep 4 
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0.38 2000986T_vs_2000986N 2 










-0.37 57689477T_rep_vs_57689477N_rep 6 
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-0.37 2000986T_vs_2000986N 3 





0.37 57689477T_vs_57689477N 2 















-0.36 2000986T_vs_2000986N 3 
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0.36 2000639T_vs_2000639N 2 
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-0.34 57689477T_vs_57689477N 2 
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-0.33 57689477T_vs_57689477N 3 











-0.33 57689477T_rep_vs_57689477N_rep 2 
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-0.32 990172T_vs_990172N 3 
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0.31 990172T_vs_990172N 5 
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0.31 57689477T_rep_vs_57689477N_rep 2 
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0.3 57689477T_rep_vs_57689477N_rep 2 
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-0.29 57689477T_vs_57689477N 2 
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-0.28 2000892T_vs_2000892N 3 
199 
 




















































0.28 57689477T_vs_57689477N 2 
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Gene MISO identifier for the ASE Max ΔΨ TN with max ΔΨ #TN 
















-0.27 2000892T_vs_2000892N 3 



































-0.26 2000892T_vs_2000892N 3 
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0.26 2000986T_vs_2000986N 2 








































0.25 57689477T_rep_vs_57689477N_rep 3 
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0.25 43658255T_vs_43658255N 2 
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-0.25 2000986T_vs_2000986N 2 








































-0.24 2000721T_vs_2000721N 3 
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0.23 57689477T_vs_57689477N 2 
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0.21 980437T_vs_980437N 2 
TMEM129 chr4:1717679:1719155:-@chr4:1719243:1719402:-@chr4:1719879:1720353:- -0.21 980417T_vs_980417N 2 
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Sup Table 6 Ontology (GO) Biological Process enrichment tumor-associated ASEs 
Count describes the number of query genes involved in the GO term. % equal to number of query genes involved in the GO 
term /total the database (320).  P is the p-value for enrichment, computed by the standard DAVID "EASE score" (a 
conservative modification of Fisher's test).Pop Hits: Genome genes involved in the GO term. Fold enrichment is a measure of 
the magnitude of enrichment. (Count/List Total)/(Pop Hits/Pop Total); List Total is 243, the total number of query genes that 
are in any GO Biological Process term; Pop Total is 13528, which is the total number of genes in GO Biological Process terms. 
"Bonferroni", "Benjamini", and "FDR" columns as returned by DAVID and are different method for multiple testing correction 
of p value. 
Term Count % P-value Pop Hits 
Fold 
Enrichment Bonferroni Benjamini FDR 
GO:0007010  cytoskeleton 
organization 25 0.83 1.04E-06 436 3.19 1.44E-03 1.44E-03 1.71E-03 
GO:0030036  actin cytoskeleton 
organization 17 0.56 3.06E-06 226 4.19 4.24E-03 2.12E-03 5.03E-03 
GO:0030029  actin filament-
based process 17 0.56 6.98E-06 241 3.93 9.65E-03 3.23E-03 1.15E-02 
GO:0006796  phosphate 
metabolic process 35 1.16 1.28E-04 973 2.00 1.63E-01 0.04 0.21 
GO:0006793  phosphorus 
metabolic process 35 1.16 1.28E-04 973 2.00 1.63E-01 0.04 0.21 
GO:0006468  protein amino 
acid phosphorylation 26 0.86 3.79E-04 667 2.17 4.09E-01 0.10 0.62 
GO:0016310  phosphorylation 28 0.93 1.11E-03 800 1.95 7.88E-01 0.23 1.82 
GO:0018108  peptidyl-tyrosine 
phosphorylation 6 0.20 1.32E-03 46 7.26 8.41E-01 0.23 2.16 
GO:0018212  peptidyl-tyrosine 
modification 6 0.20 1.61E-03 48 6.96 8.93E-01 0.24 2.61 
GO:0050773  regulation of 
dendrite development 4 0.13 2.19E-03 15 14.85 9.53E-01 0.29 3.55 
GO:0034330  cell junction 6 0.20 3.45E-03 57 5.86 9.92E-01 0.38 5.53 
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Term Count % P-value Pop Hits 
Fold 
Enrichment Bonferroni Benjamini FDR 
organization 
GO:0046777  protein amino 
acid autophosphorylation 7 0.23 4.15E-03 85 4.58 9.97E-01 0.41 6.62 
GO:0007517  muscle organ 
development 11 0.37 4.72E-03 211 2.90 9.99E-01 0.42 7.50 
GO:0010608  
posttranscriptional regulation of 
gene expression 
11 0.37 4.72E-03 211 2.90 9.99E-01 0.42 7.50 
GO:0034329  cell junction 
assembly 5 0.17 6.02E-03 41 6.79 1.00E+00 0.48 9.46 
GO:0007169  transmembrane 
receptor protein tyrosine kinase 
signaling pathway 
11 0.37 7.12E-03 224 2.73 1.00E+00 0.51 11.09 
GO:0022610  biological 
adhesion 23 0.76 7.41E-03 701 1.83 1.00E+00 0.50 11.52 
GO:0007155  cell adhesion 23 0.76 7.49E-03 700 1.83 1.00E+00 0.48 11.63 
GO:0007044  cell-substrate 
junction assembly 4 0.13 7.69E-03 23 9.68 1.00E+00 0.47 11.93 
GO:0051270  regulation of cell 
motion 10 0.33 8.00E-03 193 2.88 1.00E+00 0.46 12.39 
GO:0030334  regulation of cell 
migration 9 0.30 1.11E-02 169 2.96 1.00E+00 0.56 16.77 
GO:0006417  regulation of 
translation 8 0.27 1.16E-02 137 3.25 1.00E+00 0.56 17.48 
GO:0030030  cell projection 
organization 14 0.47 1.53E-02 368 2.12 1.00E+00 0.64 22.40 
GO:0010559  regulation of 
glycoprotein biosynthetic 
process 
3 0.10 1.58E-02 11 15.18 1.00E+00 0.63 23.01 
GO:0007017  microtubule-
based process 11 0.37 1.58E-02 253 2.42 1.00E+00 0.62 23.08 
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Term Count % P-value Pop Hits 
Fold 
Enrichment Bonferroni Benjamini FDR 
GO:0030031  cell projection 
assembly 6 0.20 1.65E-02 83 4.02 1.00E+00 0.62 23.95 
GO:0007160  cell-matrix 
adhesion 6 0.20 2.17E-02 89 3.75 1.00E+00 0.70 30.26 
GO:0030866  cortical actin 
cytoskeleton organization 3 0.10 2.18E-02 13 12.85 1.00E+00 0.69 30.46 
GO:0040012  regulation of 
locomotion 9 0.30 2.22E-02 192 2.61 1.00E+00 0.69 30.95 
GO:0010171  body 
morphogenesis 3 0.10 2.52E-02 14 11.93 1.00E+00 0.72 34.27 
GO:0030865  cortical 
cytoskeleton organization 3 0.10 2.52E-02 14 11.93 1.00E+00 0.72 34.27 
GO:0034622  cellular 
macromolecular complex 
assembly 
12 0.40 2.80E-02 318 2.10 1.00E+00 0.74 37.35 
GO:0031589  cell-substrate 
adhesion 6 0.20 3.12E-02 98 3.41 1.00E+00 0.77 40.64 
GO:0030032  lamellipodium 
assembly 3 0.10 3.24E-02 16 10.44 1.00E+00 0.77 41.88 
GO:0030155  regulation of cell 
adhesion 7 0.23 3.65E-02 137 2.84 1.00E+00 0.80 45.82 
GO:0006446  regulation of 
translational initiation 4 0.13 3.66E-02 41 5.43 1.00E+00 0.79 45.88 
GO:0007015  actin filament 
organization 5 0.17 3.99E-02 72 3.87 1.00E+00 0.81 48.88 
GO:0007167  enzyme linked 
receptor protein signaling 
pathway 
12 0.40 4.38E-02 342 1.95 1.00E+00 0.83 52.16 
GO:0000226  microtubule 




Sup Table 7 Gene Ontology (GO) Cellular Component enrichment for genes with candidate tumor-associated ASEs 
Count describes the number of query genes involved in the GO term. % equal to number of query genes involved in the GO 
term /total the database (320).  P is the p-value for enrichment, computed by the standard DAVID "EASE score" (a 
conservative modification of Fisher's test).Pop Hits: Genome genes involved in the GO term. Fold enrichment is a measure of 
the magnitude of enrichment. (Count/List Total)/(Pop Hits/Pop Total); List Total is 218, the total number of query genes that 
are in any GO Biological Process term; Pop Total is 12,782, which is the total number of genes in GO Biological Process terms. 
"Bonferroni", "Benjamini", and "FDR" columns as returned by DAVID and are different method for multiple testing correction 
of p value. 
Term Count % P-value Pop Hits 
Fold 
Enrichment Bonferroni Benjamini FDR 
GO:0015629 actin cytoskeleton 21 0.70 3.15E-08 269 4.58 1.07E-05 1.07E-05 4.28E-05 
GO:0042641 actomyosin 6 0.20 8.02E-05 27 13.03 2.69E-02 0.01 0.1 
GO:0005768 endosome 17 0.56 9.50E-05 315 3.16 3.18E-02 0.01 0.1 
GO:0043232 intracellular non-
membrane-bounded organelle 67 2.23 2.46E-04 2596 1.51 8.02E-02 0.02 0.3 
GO:0043228 non-membrane-bounded 
organelle 67 2.23 2.46E-04 2596 1.51 8.02E-02 0.02 0.3 
GO:0005856 cytoskeleton 42 1.40 2.48E-04 1381 1.78 8.10E-02 0.02 0.3 
GO:0016281 eukaryotic translation 
initiation factor 4F complex 4 0.13 3.76E-04 9 26.06 0.12 0.02 0.5 
GO:0031252 cell leading edge 10 0.33 5.73E-04 138 4.25 0.18 0.03 0.8 
GO:0001725 stress fiber 5 0.17 6.58E-04 24 12.22 0.20 0.03 0.9 
GO:0044449 contractile fiber part 9 0.30 6.74E-04 113 4.67 0.20 0.03 0.9 
GO:0043034 costamere 4 0.13 7.20E-04 11 21.32 0.22 0.02 1.0 
GO:0005938 cell cortex 10 0.33 8.60E-04 146 4.02 0.25 0.03 1.2 
GO:0032432 actin filament bundle 5 0.17 9.01E-04 26 11.28 0.26 0.03 1.2 
GO:0043292 contractile fiber 9 0.30 1.06E-03 121 4.36 0.30 0.03 1.4 
GO:0016323 basolateral plasma 
membrane 11 0.37 2.46E-03 203 3.18 0.57 0.06 3.3 
GO:0030016 myofibril 8 0.27 2.82E-03 111 4.23 0.62 0.06 3.8 
GO:0030055 cell-substrate junction 8 0.27 2.97E-03 112 4.19 0.64 0.06 4.0 
GO:0005829 cytosol 37 1.23 3.18E-03 1330 1.63 0.66 0.06 4.2 
GO:0030054 cell junction 19 0.63 3.18E-03 518 2.15 0.66 0.06 4.3 
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Term Count % P-value Pop Hits 
Fold 
Enrichment Bonferroni Benjamini FDR 
GO:0005769 early endosome 7 0.23 3.21E-03 85 4.83 0.66 0.06 4.3 
GO:0000118 histone deacetylase 
complex 5 0.17 5.00E-03 41 7.15 0.82 0.08 6.6 
GO:0017053 transcriptional repressor 
complex 5 0.17 5.00E-03 41 7.15 0.82 0.08 6.6 
GO:0016585 chromatin remodeling 
complex 6 0.20 7.08E-03 71 4.95 0.91 0.11 9.2 
GO:0005802 trans-Golgi network 5 0.17 7.55E-03 46 6.37 0.92 0.11 9.8 
GO:0042995 cell projection 22 0.73 7.70E-03 697 1.85 0.93 0.11 10.0 
GO:0044431 Golgi apparatus part 12 0.40 1.18E-02 294 2.39 0.98 0.15 14.9 
GO:0060053 neurofilament 
cytoskeleton 3 0.10 1.18E-02 10 17.59 0.98 0.15 14.9 
GO:0045178 basal part of cell 4 0.13 1.40E-02 30 7.82 0.99 0.17 17.4 
GO:0005912 adherens junction 8 0.27 1.66E-02 155 3.03 1.00 0.19 20.4 
GO:0031090 organelle membrane 29 0.96 1.90E-02 1096 1.55 1.00 0.21 22.9 
GO:0016604 nuclear body 8 0.27 2.46E-02 168 2.79 1.00 0.25 28.7 
GO:0048471 perinuclear region of 
cytoplasm 11 0.37 2.53E-02 288 2.24 1.00 0.25 29.5 
GO:0001726 ruffle 5 0.17 2.70E-02 67 4.38 1.00 0.26 31.1 
GO:0044451 nucleoplasm part 17 0.56 2.73E-02 555 1.80 1.00 0.25 31.4 
GO:0070161 anchoring junction 8 0.27 2.75E-02 172 2.73 1.00 0.25 31.6 
GO:0005925 focal adhesion 6 0.20 2.98E-02 102 3.45 1.00 0.26 33.8 
GO:0030027 lamellipodium 5 0.17 3.10E-02 70 4.19 1.00 0.26 34.9 
GO:0044430 cytoskeletal part 25 0.83 3.32E-02 952 1.54 1.00 0.27 36.8 
GO:0005924 cell-substrate adherens 
junction 6 0.20 3.44E-02 106 3.32 1.00 0.27 37.9 
GO:0045202 synapse 12 0.40 4.00E-02 355 1.98 1.00 0.31 42.7 
GO:0005794 Golgi apparatus 23 0.76 4.02E-02 872 1.55 1.00 0.30 42.8 
GO:0019898 extrinsic to membrane 15 0.50 4.24E-02 494 1.78 1.00 0.31 44.6 
GO:0005604 basement membrane 5 0.17 4.35E-02 78 3.76 1.00 0.31 45.5 
GO:0012505 endomembrane system 21 0.70 4.38E-02 782 1.57 1.00 0.30 45.7 
GO:0016023 cytoplasmic membrane-
bounded vesicle 16 0.53 4.80E-02 550 1.71 1.00 0.32 48.8 
GO:0044420 extracellular matrix part 6 0.20 4.91E-02 117 3.01 1.00 0.32 49.6 
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Sup Table 8 Gene Ontology (GO) Molecular Function enrichment for genes with candidate tumor-associated ASEs 
Count describes the number of query genes involved in the GO term. % equal to number of query genes involved in the GO 
term /total the database (320).  P is the p-value for enrichment, computed by the standard DAVID "EASE score" (a 
conservative modification of Fisher's test).Pop Hits: Genome genes involved in the GO term. Fold enrichment is a measure of 
the magnitude of enrichment. (Count/List Total)/(Pop Hits/Pop Total); List Total is 232, the total number of query genes that 
are in any GO Biological Process term; Pop Total is 12,983, which is the total number of genes in GO Biological Process terms. 
"Bonferroni", "Benjamini", and "FDR" columns as returned by DAVID and are different method for multiple testing correction 
of p value. 
Term Count % P-value Pop Hits 
Fold 
Enrichment Bonferroni Benjamini FDR 
GO:0003779 actin binding 24 0.80 1.84E-08 326 4.12 7.74E-06 7.74E-06 2.59E-05 
GO:0008092 cytoskeletal protein 
binding 28 0.93 3.10E-07 504 3.11 1.30E-04 6.52E-05 4.36E-04 
GO:0019899 enzyme binding 24 0.80 5.92E-05 523 2.57 2.46E-02 8.25E-03 8.31E-02 
GO:0004672 protein kinase activity 26 0.86 7.88E-05 606 2.40 3.26E-02 8.24E-03 0.11 
GO:0000166 nucleotide binding 61 2.03 5.36E-04 2245 1.52 2.02E-01 4.40E-02 0.75 
GO:0004674 protein serine/threonine 
kinase activity 19 0.63 6.86E-04 430 2.47 2.50E-01 4.69E-02 0.96 
GO:0019901 protein kinase binding 10 0.33 1.26E-03 147 3.81 4.10E-01 7.27E-02 1.75 
GO:0004713 protein tyrosine kinase 
activity 10 0.33 2.89E-03 166 3.37 7.03E-01 0.14 3.98 
GO:0032559 adenyl ribonucleotide 
binding 42 1.40 3.17E-03 1497 1.57 7.36E-01 0.14 4.36 
GO:0032553 ribonucleotide binding 49 1.63 3.47E-03 1836 1.49 7.68E-01 0.14 4.77 
GO:0032555 purine ribonucleotide 
binding 49 1.63 3.47E-03 1836 1.49 7.68E-01 0.14 4.77 
GO:0005524 ATP binding 41 1.36 4.35E-03 1477 1.55 8.40E-01 0.15 5.94 
GO:0003723 RNA binding 24 0.80 4.57E-03 718 1.87 8.54E-01 0.15 6.23 
GO:0019900 kinase binding 10 0.33 4.75E-03 179 3.13 8.65E-01 0.14 6.47 
GO:0017016 Ras GTPase binding 7 0.23 5.64E-03 91 4.30 9.07E-01 0.16 7.63 
GO:0030554 adenyl nucleotide binding 42 1.40 7.80E-03 1577 1.49 9.63E-01 0.20 10.42 
GO:0017076 purine nucleotide binding 49 1.63 8.01E-03 1918 1.43 9.66E-01 0.19 10.68 
GO:0031267 small GTPase binding 7 0.23 9.26E-03 101 3.88 9.80E-01 0.21 12.26 
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Term Count % P-value Pop Hits 
Fold 
Enrichment Bonferroni Benjamini FDR 
GO:0001883 purine nucleoside binding 42 1.40 1.00E-02 1601 1.47 9.85E-01 0.21 13.17 
GO:0004437 inositol or 
phosphatidylinositol phosphatase 
activity 4 0.13 1.07E-02 26 8.61 9.89E-01 0.21 14.01 
GO:0001882 nucleoside binding 42 1.40 1.12E-02 1612 1.46 9.91E-01 0.21 14.60 
GO:0051020 GTPase binding 7 0.23 1.32E-02 109 3.59 9.96E-01 0.23 17.00 
GO:0005543 phospholipid binding 9 0.30 1.39E-02 177 2.85 9.97E-01 0.23 17.84 
GO:0051015 actin filament binding 5 0.17 1.45E-02 53 5.28 9.98E-01 0.23 18.52 
GO:0004385 guanylate kinase activity 3 0.10 1.56E-02 11 15.26 9.99E-01 0.24 19.81 
GO:0005198 structural molecule 
activity 20 0.66 1.84E-02 634 1.77 1.00E+00 0.27 23.00 
GO:0016776 phosphotransferase 
activity, phosphate group as acceptor 4 0.13 2.05E-02 33 6.78 1.00E+00 0.28 25.23 
GO:0017048 Rho GTPase binding 4 0.13 2.97E-02 38 5.89 1.00E+00 0.37 34.52 
GO:0004714 transmembrane receptor 
protein tyrosine kinase activity 5 0.17 3.13E-02 67 4.18 1.00E+00 0.38 36.03 
GO:0016791 phosphatase activity 10 0.33 3.43E-02 249 2.25 1.00E+00 0.40 38.71 
GO:0043423 3-phosphoinositide-
dependent protein kinase binding 2 0.07 3.53E-02 2 55.96 1.00E+00 0.40 39.61 
GO:0008307 structural constituent of 
muscle 4 0.13 3.84E-02 42 5.33 1.00E+00 0.41 42.30 
GO:0005516 calmodulin binding 7 0.23 3.90E-02 140 2.80 1.00E+00 0.41 42.85 
GO:0019205 nucleobase, nucleoside, 
nucleotide kinase activity 4 0.13 4.07E-02 43 5.21 1.00E+00 0.41 44.25 
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Sup Table 9 Genes with candidate tumor-associated ASEs likely to lead to functional changes based on previous 
literature 
All ASEs listed here passed Filters 1 and 2. "Cancer gene?" column indicate known cancer-related gene in COSMIC; Y =Yes, 
N=No. MXE = mutually exclusive exon. 



































CD44 Y Many 
Multiple isoforms 
contribute to gastric 
tumorigenesis. 
 (da Cunha et al., 
2010; Muller et al., 

















FGFR2 Y Unknown 
Tumor-associated 
spliceform contains exon 
IIIb  
(Druillennec et al., 
2012; Ricol et al., 
1999) (Ishii et al., 
1995; Shin et al., 
2000) 





MST1R Y Β-chain  
Tumor-associated 
spliceform lacks exon 11 
and is associated with 
motility and invasion 
 (Collesi et al., 
1996) Y Y Y  
Gastric 
cancer 
CTNND1 Y Coiled coil 
Tumor-associated 
spliceform lacking exons 2 
and 3 may lead to more 
invasiveness. 
 (Keirsebilck et al., 
1998; Liu et al., 
2009; Montonen et 
al., 2001; Talvinen 
et al., 2010) 




















































Loss of exon 16-17 cannot 
bind to either spectrin or 
actin, cannot link 
transmembrane proteins to 
the cytoskeleton. 










do not have exon 11aa, 
which contains a Ser at a 
site likely to be targeted 
for regulated 
phosphorylation.  
(Honkaniemi et al., 













contains exon 10-14 and 
16 




Sup Table 10 Primers for ASEs in genes in Sup Table9 
MISO identifier is the identifier of the ASE and encodes the locations of the upstream, downstream, and skipped exons. PCR 
product lengths is the expected PCR product sizes with/without the skipped exon. MXE = mutually exclusive exon. 








valida-tion Forward Reverse 


















































































































Sup Table 11 Candidate tumor specific ASEs (passing Filters 1 and 3) 
T =Tumor, N=Normal, TN=Tumor normal pair; MISO id for the ASE constitutes of the location of upstream, downstream and skipped 
exon; Density difference measure the proportion of T with Ѱ value higher than all N; 95% N represent the Ψ value where 95% of N 
below. ΔΨ is the largest Ψ value of the tumor density peak minus the smaller value between largest Ψ value of the normal density peak 
and 95% normal density. 
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0.63 0.12 0.21 N N N N 
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0.54 0.28 0.60 N N N N 
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@chr17:19185268:19185390: +  






@chr14:101302504:101302637: +  










0.08 0.25 0.45 N N N N 
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Sup Table 12 3’ splice sites without CAG to → CTG mutations for evaluating the 
proportion of un-mutated sites associated with aberrant splicing 
IC = inadequate coverage at site of hypothetical mutation; high 3' FPKM = overall FPKM is high 
because of very high coverage in the 3' most exon. 
Gene symbol Exon FPKM  Finding Ensembl transcript 
HTRA3 2 2.13 No aberration ENST00000307358 
PPFIBP2 17 2.13 No aberration ENST00000299492 
SMG7 20 2.13 IC ENST00000367537 
KIF3B 5 2.13 IC; high 3' FPKM ENST00000375712 
LSP1 2 2.4 IC; high 3' FPKM ENST00000381775 
ARHGAP26 13 2.4 No aberration ENST00000274498 
DHDS 5 2.62 No aberration ENST00000374194 
RSL24D1 2 2.62 IC; high 3' FPKM ENST00000260443 
ITGA1 27 4 No aberration ENST00000282588 
CCBP2 3 4.01 IC ENST00000496604 
AGPAT6 7 4.62 No aberration ENST00000396987 
RHBDL2 2 4.63 No aberration ENST00000372985 
MEF2D 6 5.3 No aberration ENST00000348159 
TMEM98 3 5.32 No aberration ENST00000439138 
HDAC7 21 5.38 IC ENST00000380610 
KDM5C 20 5.38 No aberration ENST00000375401 
TIAM1 4 5.3 No aberration ENST00000399841 
AP3D1 6 5.4 No aberration ENST00000355272 
PRKDC 45 6.11 IC ENST00000523565 
PDE4DIP 6 6.33 IC ENST00000369359 
UBAP2L 14 8.95 No aberration ENST00000271877 
TRIM26 5 9.24 No aberration ENST00000454678 
PCIG1 13 9.28 No aberration ENST00000443130 
RCC1 12 15.12 No aberration ENST00000398962 
INPP5K 12 15.13 No aberration ENST00000406424 
IDH1 4 25.4 No aberration ENST00000345146 
RTN2 5 25.42 No aberration ENST00000245923 
SFRS16 5 27.52 No aberration ENST00000221455 
BRF1 2 27.9 No aberration ENST00000327359 
 
